Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors

ABSTRACT

Disclosed are compounds of formula I ##STR1## wherein R 1  represents hydrogen, lower alkyl, substituted lower alkyl, nitro, halogen, free, etherified or esterified hydroxy, free, etherified, oxidized etherified or esterified mercapto, unsubstituted, mono- or disubstituted amino, ammonio, free or functionally modified sulfo, free or functionally modified formyl, C 2  -C 20  -acyl, cyano, free or functionally modified carboxy; and R 2  represents hydrogen, lower alkyl, substituted lower alkyl, halogen; free, etherified or esterified hydroxy; free, etherified, oxidized etherified or esterified mercapto; free or functionally modified carboxy, or acyl; the 7,8-dihydro derivatives thereof; and compounds of the formula I* ##STR2## wherein n denotes 0, 1, 2, 3 or 4, and R 1  and R 2  are as defined above under formula I and salts thereof; e.g. as aromatase inhibitors; pharmaceutical compositions containing these compounds; the use of these compounds for the treatment of conditions responsive to e.g. aromatase inhibition in mammals; processes and intermediates for preparing these compounds.

REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 747,195 filedJune 20, 1985, now abandoned, which is a continuation-in-part ofapplication Ser. No. 622,421 filed June 20, 1984, now U.S. Pat. No.4,617,307, and of application Ser. No. 451,902, filed Dec. 21, 1982, nowU.S. Pat. No. 4,588,732.

SUMMARY OF THE INVENTION

The invention relates to substituted imidazo[1,5-a]pyridine derivativesand other substituted bicyclic derivatives which have valuablepharmacological properties e.g. as aromatase inhibitors, topharmaceutical compositions containing these compounds, to the use ofthese compounds for the treatment of conditions responsive to e.g.aromatase inhibition by administration of an effective amount of saidcompounds or compositions to mammals including man, to processes forpreparing these compounds, to intermediates and to processes forpreparing these intermediates.

DETAILED DESCRIPTION OF THE INVENTION

Particularly, the invention relates to the substitutedimidazo[1,5-a]pyridine derivatives of the formula I ##STR3## wherein R₁represents hydrogen, lower alkyl, substituted lower alkyl, nitro,halogen, free, etherified or esterified hydroxy, free, etherified,oxidised etherified or esterified mercapto, unsubstituted, mono- ordisubstituted amino, ammonio, free or functionally modified sulfo, freeor functionally modified formyl, C₂ -C₂₀ -acyl, cyano, free orfunctionally modified carboxy; and R₂ represents hydrogen, lower alkyl,substituted lower alkyl, halogen; free, etherified or esterifiedhydroxy; free, etherified, oxidised etherified or esterified mercapto;free or functionally modified carboxy, or acyl; the 7,8-dihydroderivatives thereof; and compounds of the formula I* ##STR4## wherein ndenotes 0, 1, 2, 3 or 4, and R₁ and R₂ are as defined above underformula I, in a compound of formula I* it being possible for the twosubstituents C₆ H₄ --R₁ and R₂ to be attached to any of the saturatedcarbon atoms of the saturated ring, either both to the same carbon atomor to different carbon atoms; stereoisomers, mixtures of thesestereoisomers; or pharmaceutically acceptable salts thereof.

The term "lower" means that groups so designated usually contain up toand including 7, and preferably up to and including 4, carbon atoms.

The compounds of formula I* as well as certain 7,8-dihydro derivativesof formula I contain at least one asymmetric carbon atom. They can befound as R- and S-enantiomers as well as enantiomeric mixtures thereof,such as a racemate. The present invention is intended to include allthese forms, also those further isomers, and mixtures of at least twoisomers, for example a diastereoisomeric mixture of enantiomericmixture, which become possible if one or more further asymmetriccenter(s) are present within the molecule.

Lower alkyl is e.g. n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl ortert-butyl, also n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl orn-heptyl, but preferably ethyl and especially methyl.

Substituted lower alkyl R₁ is preferably substituted by hydroxy,etherified hydroxy, such as lower alkoxy, esterified hydroxy, such aslower alkanoyloxy, acyl, such as lower alkanoyl, amino, mono- ordisubstituted amino, such as lower alkylamino or di-lower alkylamino,halogen, preferably fluoro, free or functionally modified sulfo,preferably sulfo or sulfamoyl, or free or functionally modified carboxy,such as carboxy, lower alkoxycarbonyl, carbamoyl; or cyano.

Substituted lower alkyl R₂ is preferably substituted by aryl or free orfunctionally modified carboxy, especially carboxy or loweralkoxycarbonyl.

Halogen is e.g. bromo or iodo, preferably fluoro and especially chloro.

Etherified hydroxy is especially lower alkoxy, also, for example,aryloxy or aryl-lower alkoxy. Esterified hydroxy is e.g. acyloxy,preferably lower alkanoyloxy, but may be also e.g. aroyloxy or loweralkoxycarbonyloxy.

Etherified mercapto is in particular lower alkylthio, also e.g. arylthioor aryl-lower alkylthio. Oxidised etherified mercapto is e.g.aryl-sulfinyl or aryl-sulfonyl and especially lower alkylsulfinyl orlower alkylsulfonyl. Esterified mercapto is e.g. acylthio, such as loweralkanoylthio.

Monosubstituted amino is in particular lower alkylamino, further e.g.arylamino, aryl-lower alkylamino or acylamino, especially loweralkanoylamino, but also e.g. aroylamino.

Disubstituted amino is in particular di-lower alkylamino, also loweralkyleneamino, oxa-, thia- or aza-lower alkyleneamino (in the latter ofwhich the azo-nitrogen atom may be substituted e.g. by a hydrocarbonradical, such as lower alkyl), such as N-morpholino, N-thiomorpholino oroptionally 4-lower alkylsubstituted N-piperazino.

Ammonio comprises e.g. quaternary ammonium salts derived fromcorresponding disubstituted amino groups mentioned above, which containas quaternary substituent e.g. optionally substituted lower alkyl,preferably lower alkyl, hydroxy- or halo-lower alkyl or aryl-loweralkyl. Especially ammonio is tri-lower alkylammonio, such astrimethylammonio. The ammonium salts correspond to the salts definedhereinafter, especially the salts mentioned in particular as beingpharmaceutically acceptable, non-toxic acid addition salts, and moreespecially to those salts formed with hydrohalic acids, sulfuric orphosphoric acid.

Free or functionally modified sulfo is e.g. sulfo (--SO₃ H), esterifiedsulfo, such as lower alkoxysulfonyl, amidated sulfo, such as sulfamoyl,lower alkylsulfamoyl or di-lower alkylsulfamoyl, or sulfonyl halide,such as sulfonyl chloride; and is preferably sulfo or sulfamoyl.

Free or functionally modified formyl is preferably formyl or iminomethyl(--CH═NH) which may be N-substituted be free, etherified or esterifiedhydroxy, such as hydroxy, lower alkoxy or lower alkanoyloxy, by loweralkyl, aryl or amino; but may be also an acetal, such as a di-loweralkylacetal, e.g. dimethylacetal.

Acyl, usually containing 1-20 carbon atoms, is the corresponding radicalof a carboxylic acid, preferably aroyl or halo-C₂ -C₇ -alkanoyl andespecially lower alkanoyl. C₁ -Alkanoyl corresponds to formyl.

Free or functionally modified carboxy is e.g. carboxy, esterifiedcarboxy, preferably lower alkoxycarbonyl; amidated carboxy, preferablycarbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl orhydroxycarbamoyl. Further comprised are 5-tetrazolyl or unsubstituted orlower alkylsubstituted 4,5-dihydro-2-oxazolyl.

Aryl, as such or within radicals like aryloxy, aryl-lower alkylthio,arylsulfonyl, arylamino etc., is e.g. 1- or 2-naphthyl, preferablyphenyl which is substituted, especially monosubstituted, by e.g. loweralkyl, lower alkoxy and/or halogen, and is in particular phenyl. Aroyl,as such or within radicals like aroyloxy etc., is arylcarbonyl, inparticular benzoyl.

Lower alkoxy is preferably methoxy or ethoxy, also e.g. n-propoxy,isopropoxy, n-butoxy, isobutoxy or tert-butoxy.

Lower alkanoyloxy is e.g. formyloxy, acetoxy, propionyloxy orpivaloyloxy.

Lower alkanoyl is e.g. formyl, acetyl, propionyl or pivaloyl. Halo-C₂-C₇ -alkanoyl is preferably trifluoroacetyl. Lower alkanoylamino ispreferably acetylamino or propionylamino, but also e.g. formylamino.

Lower alkoxycarbonyl is preferably methoxycarbonyl or ethoxycarbonyl.Lower alkoxycarbonyloxy is e.g. methoxycarbonyloxy or ethoxycarbonyloxy.

Lower alkylamino is e.g. methylamino, ethylamino, n-propylamino orisopropylamino. Di-lower alkylamino is e.g. dimethylamino,ethylmethylamino or diethylamino. Lower alkyleneamino contains e.g. from2 to 7, preferably 4 to 6, ring carbon atoms and is, for example,N-pyrrolidino or N-piperidino.

Lower alkylthio is e.g. methylthio, ethylthio, n-propylthio orisopropylthio, while lower alkylsulfinyl is e.g. methylsulfinyl, andlower alkylsulfonyl is e.g. methylsulfonyl or ethylsulfonyl. Loweralkanoylthio is preferably formylthio or acetylthio.

Lower alkoxysulfonyl is e.g. methoxysulfonyl or ethoxysulfonyl. Loweralkylsulfamoyl is e.g. N-methyl- or N-ethylsulfamoyl, while di-loweralkylsulfamoyl is e.g. dimethyl- or diethylsulfamoyl.

Lower alkylcarbamoyl is e.g. N-methylcarbamoyl or N-ethylcarbamoyl,while di-lower alkylcarbamoyl is e.g. dimethyl- or diethylcarbamoyl.

The compounds of the invention form acid addition salts with acids,particularly pharmaceutically acceptable salts, with conventional acids,for example mineral acids, e.g. hydrochloric acid, sulfuric orphosphoric acid, or organic acids, for example aliphatic or aromaticcarboxylic or sulfonic acids, e.g. formic, acetic, propionic, succinic,glycolic, lactic, malic, tartaric, citric, ascorbic, maleic, fumaric,hydroxymaleic, pyruvic, phenylacetic, benzoic, 4-aminobenzoic,anthranilic, 4-hydroxybenzoic, salicylic, 4-aminosalicylic, pamoic,gluconic, nicotinic, methanesulfonic, ethanesulfonic,halobenzenesulfonic, toluenesulfonic, naphthalenesulfonic, sulfanilic orcyclohexylsulfamic acid. Salts may also be formed with amino acids, suchas arginine and lysine.

Compounds of the invention having acidic groups, for example a freecarboxy or sulfo group, form especially metal or ammonium salts, such asalkali metal or alkaline earth metal salts, e.g. sodium, potassium,magnesium or calcium salts, as well as ammonium salts, which are formedwith ammonia or suitable organic amines. There come into considerationfor the salt formation especially aliphatic, cycloaliphatic,cycloaliphatic-aliphatic or araliphatic primary, secondary or tertiarymono-, di- or poly-amines, as well as heterocyclic bases, such as loweralkylamines, for example di- or tri-ethylamine, hydroxy-loweralkylamines, such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine ortris-(2-hydroxyethyl)-amine, basic aliphatic esters or carboxylic acids,e.g. 4-aminobenzoic acid 2-diethylaminoethyl ester, loweralkyleneamines, e.g. 1-ethylpiperidine, cycloalkylamines, e.g.dicyclohexylamine, benzylamines, e.g. N,N'-dibenzylethylenediamine, orbases of the pyridine typ, e.g. pyridine, collidine or quinoline.

In the presence of several acidic or basic groups, mono- or poly-saltsmay be formed. Compounds of the invention having an acidic group and abasic group may also be present in the form of inner salts, i.e. inzwitterionic form, or a part of the molecule may be present in the formof an inner salt and another part in the form of a normal salt. Thepharmaceutically acceptable salts mentioned hereinbefore are preferred.For isolation or purification it is also possible to use other saltsthan the therapeutically acceptable salts, for example the picrates.

Preferred are the compounds of formula I, wherein R₁ representshydrogen, lower alkyl; lower alkyl substituted by hydroxy, lower alkoxy,lower alkanoyloxy, lower alkanoyl, amino, lower alkylamino, di-loweralkylamino, halogen, sulfo, carboxy, lower alkoxycarbonyl, carbamoyl orcyano; nitro, halogen, hydroxy, lower alkoxy, lower alkanoyloxy,phenylsulfonyloxy, lower alkylsulfonyloxy, mercapto, lower alkylthio,lower alkylsulfinyl, lower alkylsulfonyl, lower alkanoylthio, amino,lower alkylamino, di-lower alkylamino, lower alkyleneamino,N-morpholino, N-thiomorpholino, optionally 4-lower alkylsubstitutedN-piperazino, tri-lower alkylammonio, sulfo, lower alkoxysulfonyl,sulfamoyl, lower alkylsulfamoyl, di-lower alkylsulfamoyl, formyl;iminomethyl optionally N-substituted by hydroxy, lower alkoxy, loweralkanoyloxy, lower alkyl, phenyl or amino; C₂ -C₇ -alkanoyl, benzoyl,carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di-loweralkylcarbamoyl, cyano, 5-tetrazolyl, optionally lower alkylsubstituted4,5-dihydro-2-oxazolyl or hydroxycarbamoyl; and R₂ represents hydrogen,lower alkyl, phenyl-lower alkyl, carboxy-lower alkyl, loweralkoxycarbonyl-lower alkyl, halogen, hydroxy, lower alkoxy, loweralkanoyloxy, mercapto, lower alkylthio, phenyl-lower alkylthio,phenylthio, lower alkanoylthio, carboxy, lower alkoxycarbonyl or loweralkanoyl; the 7,8-dihydro derivatives thereof; and compounds of theformula I*, wherein n denotes 0, 1, 2, 3 or 4; and R₁ and R₂ are asdefined above for compounds of formula I; it being possible for thephenyl portion within the radicals phenylsulfonyloxy; phenyliminomethyl,benzoyl, phenyl-lower alkyl, phenyl-lower alkylthio and phenylthio to beunsubstituted or substituted by lower alkyl, lower alkoxy or halogen;and in a compound of formula I* it being possible for the twosubstituents C₆ H₄ -R₁ and R₂ to be attached to any of the saturatedcarbon atoms of the saturated ring, either both to the same carbon atomor to different carbon atoms; stereoisomers, mixtures of thesestereoisomers; or pharmaceutically acceptable salts thereof.

Further preferred are the compounds of formula I, wherein R₁ representslower alkyl, lower alkyl substituted by hydroxy, amino, di-loweralkylamino, by 1 to 5 fluorine atoms, by carboxy, lower alkoxycarbonyl,carbamoyl or cyano; nitro, halogen, hydroxy, lower alkoxy, amino, loweralkylamino, di-lower alkylamino, sulfo, sulfamoyl, formyl, iminomethyl;iminomethyl N-substituted by hydroxy, lower alkoxy, lower alkanoyloxy,lower alkyl or phenyl; carboxy, lower alkoxycarbonyl, carbamoyl, loweralkylcarbamoyl, di-lower alkylcarbamoyl or cyano; and R₂ is hydrogen,lower alkyl, lower alkoxy or halogen; or compounds of the formula I*,wherein n denotes 1, 2 or 3; R₁ is as defined above for the compounds offormula I and R₂ represents hydrogen, lower alkyl, phenyl-lower alkyl,carboxyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, halogen, loweralkoxy, lower alkylthio, phenyl-lower alkylthio, phenylthio, carboxy,lower alkoxycarbonyl or lower alkanoyl; in a compound of formula I* itbeing possible for the two substituents C₆ H₄ --R₁ and R₂ to be attachedto any of the saturated carbon atoms of the saturated ring, either bothto the same carbon atom or to different carbon atoms; stereoisomers,mixtures of these stereoisomers; or pharmaceutically acceptable saltsthereof.

Especially preferred are the compounds of formula I, wherein R₁represents lower alkyl, hydroxy-lower alkyl, halogen, amino, formyl,carboxy, lower alkoxycarbonyl, carbamoyl, N-lower alkylcarbamoyl orcyano; and R₂ is hydrogen; or the compounds of formula I*, wherein ndenotes 1, 2 or 3; R₁ is as defined above for formula I and R₂represents hydrogen, lower alkylthio, lower alkoxycarbonyl, phenyl-loweralkyl, carboxy-lower alkyl or lower alkoxycarbonyl-lower alkyl; in acompound of formula I* it being possible for the two substituents C₆ H₄--R₁ and R₂ to be attached to any of the saturated carbon atoms of thesaturated ring, either both to the same carbon atom or to differentcarbon atoms; stereoisomers, mixtures of these stereoisomers orpharmaceutically acceptable salts thereof.

The invention relates especially to compounds of formula I, wherein R₁represents lower alkyl, hydroxy-C₂ -C₇ -alkyl; lower alkyl substitutedby amino, di-lower alkylamino, by 2 to 5 fluorine atoms, by carboxy,lower alkoxycarbonyl, carbamoyl or cyano; nitro, lower alkoxy, amino,lower alkylamino, di-lower alkylamino, sulfo, sulfamoyl, iminomethyl,iminomethyl N-substituted by hydroxy, lower alkoxy, lower alkanoyloxy,lower alkyl or phenyl; or R₁ may be hydroxymethyl, halogen, hydroxy,formyl, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl,di-lower alkylcarbamoyl or cyano; and R₂ is hydrogen, lower alkyl, loweralkoxy or halogen; and compounds of the formula I*, wherein n denotes 1,2 or 3; R₁ is as defined above for compounds of formula I and R₂represents hydrogen, lower alkyl, phenyl-lower alkyl, carboxy-loweralkyl, lower alkoxycarbonyl-lower alkyl, halogen, lower alkoxy, loweralkylthio, phenyl-lower alkylthio, phenylthio, carboxy, loweralkoxycarbonyl or lower alkanoyl; in a compound of formula I*, it beingpossible for the two substituents C₆ H₄ -R₁ and R₂ to be attached to anyof the saturated carbon atoms of the saturated ring, either both to thesame carbon atom or to different carbon atoms; stereoisomers, mixturesof these stereoisomers; and pharmaceutically acceptable salts thereof.

The invention relates more especially to compounds of formula I*,wherein n denotes 1, 2 or 3; R₁ represents lower alkyl, amino, loweralkylamino, di-lower alkylamino, hydroxymethyl, halogen, formyl,carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di-loweralkylcarbamoyl or cyano; and R₂ is hydrogen, lower alkyl, phenyl-loweralkyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, loweralkylthio, carboxy or lower alkoxycarbonyl; it being possible for thetwo substituents C₆ H₄ -R₁ and R₂ to be attached to any of the saturatedcarbon atoms of the saturated ring, either both to the same carbon atomor to different carbon atoms; to stereoisomers, mixtures of thesestereoisomers; and pharmaceutically acceptable salts thereof.

Particular embodiments of the invention relate to the herein citedcompounds of formula I, and compounds of the formula I* wherein n=1, 2or 3, respectively.

Generally preferred are the compounds of the invention, wherein thesubstituent C₆ H₄ -R₁ is attached to the 5- or 7-position of thebicyclic ring system, and of particular importance are those compounds,wherein C₆ H₄ -R₁ is attached to the 5-position. In compounds of theinvention, the substituent R₁ is preferably attached to the para- ormeta-position, especially to the para-position, of the phenyl ring. Theinteger n in a compound of formula I* is preferably 1, 2 or 3,especially 1 or 2 and in particular 2. Most preferred are the compoundsof formula I*.

A particular embodiment of the invention relates to the compounds offormula I* wherein n represents 2; R₁ represents hydrogen, lower alkyl,hydroxy-C₂ -C₇ -alkyl; lower alkyl substituted by amino, di-loweralkylamino, by 2 to 5 fluorine atoms, by carboxy, lower alkoxycarbonyl,carbamoyl, or cyano; nitro, lower alkoxy, amino, lower alkylamino,di-lower alkylamino, sulfo, sulfamoyl, iminomethyl, iminomethylN-substituted by hydroxy, lower alkoxy, lower alkanoyloxy, lower alkylor phenyl; and R₂ represents hydrogen; and pharmaceutically acceptablesalts thereof.

Another particular embodiment of the invention relates to the compoundsof formula I* wherein n represents 2; R₁ represents hydroxymethyl,halogen, formyl, carboxy, lower alkoxycarbonyl, carbamoyl, loweralkylcarbamoyl, di-lower alkylcarbamoyl or cyano; and R₂ representshydrogen; and parmaceutically acceptable salts thereof.

A further particular embodiment of the invention relates to thecompounds of formula I* wherein n represents 2; R₁ representshydroxymethyl, halogen, hydroxy, formyl, carboxy, lower alkoxycarbonyl,carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl or cyano; andR₂ represents lower alkyl, phenyl-lower alkyl, carboxy-lower alkyl,lower alkoxy-carbonyl-lower alkyl, lower alkylthio, carboxy or loweralkoxycarbonyl; it being possible for the two substituents C₆ H₄ -R₁ andR₂ to be attached to any of the saturated carbon atoms of the saturatedring, either both to the same carbon atoms or to different carbon atoms;to stereoisomers, mixtures of these stereoisomers; and pharmaceuticallyacceptable salts thereof.

A preferred embodiment of the invention relates to the compounds offormula I wherein R₁ represents cyano or halogen, especially cyano; andR₂ is hydrogen, lower alkyl, lower alkoxy or halogen, especiallyhydrogen; and pharmaceutically acceptable salts thereof.

A further preferred embodiment of the invention relates to the compoundsof formula I* wherein n represents 1, 2 or 3, especially 1 or 2; and inparticular 2; R₁ represents cyano or halogen, especially cyano; and R₂is hydrogen, lower alkyl, phenyl-lower alkyl, carboxy-lower alkyl, loweralkoxycarbonyl-lower alkyl, lower alkylthio, carboxy or loweralkoxycarbonyl, especially hydrogen; the two substituents C₆ H₄ -R₁ andR₂ to be attached to any of the saturated carbon atoms of the saturatedring, either both to the same carbon atom or to different carbon atoms;stereoisomers, mixtures of these stereoisomers and pharmaceuticallyacceptable salts thereof.

Further preferred are the said compounds of formula I* wherein thesubstituents C₆ H₄ -R₁ and R₂ are both attached at the 5-position of thebicyclic ring system; and R₁ represents para-cyano.

A further particular embodiment of the invention are the compounds offormula Ia ##STR5## wherein R₁ represents cyano, nitro or C₁ -C₄ -alkyl,the 7,8-dihydro derivatives thereof and the 5,6,7,8-tetrahydroderivatives thereof of the formula Ib ##STR6## wherein R₁ is as definedunder formula Ia and R₂ is hydrogen, C₁ -C₄ -alkyl, aryl-C₁ -C₄ -alkyl,halogen, etherified or esterified hydroxy, etherified or esterifiedmercapto, carboxy-C₁ -C₄ -alkyl, C₁ -C₄ -alkoxycarbonyl-C₁ -C₄ -alkyl orC₁ -C₄ -alkanoyl, stereoisomers, mixtures of these stereoisomers andsalts of these compounds.

The 5,6,7,8-tetrahydro-derivatives of the formula Ib have a chiralC-atom in the 5-position. The 5R- and the 5S-enantiomers as well as the5(R,S)-racemate fall within the scope of the present invention.

The generic terms used for the compounds of formulae Ia and Ibpreferably are defined as follows:

C₁ -C₄ -Alkyl R₁ or R₂ is, for example, ethyl, n-propyl, isopropyl,n-butyl, sec-butyl, or tert-butyl and preferably methyl.

Halogen R₂ is, for example, fluoro or bromo or, preferably, chloro.

Aryl-C₁ -C₄ -alkyl R₂ is, for example, benzyl.

Etherified hydroxy or mercapto R₂ is, for example, a hydroxy or mercaptogroup which is etherified by C₁ -C₄ -alkyl, for example methyl or ethyl,aryl-C₁ -C₄ -alkyl, for example benzyl, 2-phenylethyl or diphenylmethyl,or aryl, for example phenyl.

Etherified hydroxy or mercapto R₂ is, preferably, C₁ -C₄ -alkoxy, forexample methoxy or ethoxy, C₁ -C₄ -alkylthio, for example methyl- orethylthio, aryl-C₁ -C₄ -alkylthio, for example benzylthio,2-phenylethylthio or diphenylmethylthio, or is arylthio, for examplephenylthio.

Esterified hydroxy or mercapto R₂ is, for example, a hydroxy or mercaptogroup which is esterified by acyl, for example C₁ -C₄ -alkanoyl, forexample, formyl or acetyl.

Carboxy-C₁ -C₄ -alkyl R₂ is, for example, carboxymethyl or2-carboxyethyl.

C₁ -C₄ -Alkoxycarbonyl-C₁ -C₄ -alkyl R₂ is, for example, methoxy- orethoxycarbonylmethyl.

C₁ -C₄ -Alkanoyl R₂ is, for example, formyl, acetyl or propionyl. Theinvention especially relates to said compounds of the formula Ia,wherein R₁ represents cyano, and the 7,8-dihydro derivatives thereof,and the 5,6,7,8-tetrahydro derivatives thereof of the formula Ib,wherein R₁ is cyano and R₂ is hydrogen, C₁ -C₄ -alkyl, for examplemethyl or ethyl, C₁ -C₄ -alkoxy, for example methoxy or ethoxy, C₁ -C₄-alkylthio, for example methyl- or ethylthio, aryl-C₁ -C₄ -alkylthio,for example benzylthio, 2-phenylethylthio or diphenylmethylthio,arylthio, for example phenylthio, or C₁ -C₄ -alkanoyl, for exampleformyl or acetyl, and pharmaceutically acceptable acid addition salts ofa compound of the formula Ia or Ib.

Particularly preferred are said compounds of formula Ia, wherein R₁ iscyano, advantageously attached to the para-position, the 7,8-dihydroderivatives thereof and the 5,6,7,8-tetrahydro derivatives thereof ofthe formula Ib, wherein R₁ is as defined for formula Ia and R₂ ishydrogen, and pharmaceutically acceptable acid addition salts thereof.

The invention preferably relates to compounds of the formula Ic ##STR7##wherein R₂ ' is hydrogen, C₁ -C₄ -alkyl, for example methyl or ethyl, C₁-C₄ -alkoxy, for example methoxy or ethoxy, C₁ -C₄ -alkylthio, forexample methyl- or ethylthio, aryl-C₁ -C₄ -alkylthio, for examplebenzylthio, 2-phenylethylthio or diphenylmethylthio, arylthio, forexample phenylthio, or C₁ -C₄ -alkanoyl, for example formyl or acetyl,and pharmaceutically acceptable acid addition salts thereof.

Most preferred is the compound of the formula Ic, wherein R₂ ' ishydrogen, and pharmaceutically acceptable acid addition salts of thiscompound.

Also preferred are the compounds of formula Ia, wherein R₁ representshydrogen, esterified hydroxy, especially halogen or a sulfonyloxy group,such as p-toluenesulfonyloxy, benzenesulfonyloxy or mesyloxy; sulfo,amino, carbamoyl, lower alkylcarbamoyl, e.g. tert-butylcarbamoyl, or aformyl group in the form of a functional derivative, e.g.hydroxyiminomethyl; and the 5,6,7,8-tetrahydro compounds of formula Ib,wherein R₁ is as defined above for formula Ia and R₂ is hydrogen, C₁ -C₄-alkyl, aryl-C₁ -C₄ -alkyl, such as benzyl; halogen, etherified hydroxy,such as C₁ -C₄ -alkoxy; esterified hydroxy, such as acyloxy, e.g. C₁ -C₄-alkanoyloxy; etherified mercapto, such as C₁ -C₄ -alkylthio, aryl-C₁-C₄ -alkylthio, e.g. benzylthio, 2-phenylethylthio ordiphenylmethylthio, or arylthio, e.g. phenylthio; esterified mercapto,such as acylthio, e.g. C₁ -C₄ -alkanoylthio; carboxy-C₁ -C₄ -alkyl, C₁-C₄ -alkoxycarbonyl-C₁ -C₄ -alkyl or C₁ -C₄ -alkanoyl; andpharmaceutically acceptable salts thereof.

Of said compounds of formulae Ia and Ib are those of special interest,wherein R₁ represents halogen or carbamoyl, and in particular bromo.

Another preferred embodiment of the invention are compounds of formulaIa, wherein R₁ is hydrogen, esterified hydroxy, especially a sulfonyloxygroup, such as p-toluenesulfonyloxy, benzenesulfonyloxy or mesyloxy;sulfo, amino or formyl in the form of a functional derivative, such ashydroxyiminomethyl; and the 5,6,7,8-tetrahydro compounds of formula Ib,wherein R₁ is as defined above for formula Ia and R₂ is hydrogen; orwherein R₁ represents hydrogen, esterified hydroxy, especially halogenor a sulfonyloxy group, such as p-toluenesulfonyloxy, benzenesulfonyloxyor mesyloxy; sulfo, amino, carboxy, carboxy in the form of a functionalderivative, such as carbamoyl, lower alkylcarbamoyl, e.g.tert-butylcarbamoyl, formyl or a formyl group in the form of afunctional derivative, e.g. hydroxyiminomethyl, and R₂ is C₁ -C₄ -alkyl,aryl-C₁ -C₄ -alkyl, halogen, etherified or esterified hydroxy,etherified or esterified mercapto, carboxy-C₁ -C₄ -alkyl, C₁ -C₄-alkoxycarbonyl-C₁ -C₄ -alkyl or C₁ -C₄ -alkanoyl; and pharmaceuticallyacceptable salts thereof.

A further particular embodiment of the invention relates to thecompounds of formula Id ##STR8## and 5,6,7,8-tetrahydro derivativesthereof, wherein R₁ ^(a) is hydrogen, halogen, lower alkyl, loweralkoxy, hydroxy or aryl-lower alkoxy in which aryl represents phenyl orphenyl substituted by lower alkoxy, lower alkyl, halogen ortrifluoromethyl; R₂ ^(a) represents a hydrogen; C represents carboxy,lower alkoxycarbonyl, unsubstituted or mono- or di-(loweralkyl)-substituted carbamoyl, cyano, formyl, hydroxymethyl,5-tetrazolyl, 4,5-dihydro-2-oxazolyl, 4,5-dihydro-2-oxazolyl substitutedby lower alkyl, or hydroxycarbamoyl; A represents a direct bond; Brepresents phenylene; and pharmaceutically acceptable salts thereof.

A more particular embodiment thereof relates to the compounds of formulaId and 5,6,7,8-tetrahydro derivatives thereof wherein A represents adirect bond; B represents phenylene; C represents carboxy, loweralkoxycarbonyl, carbamoyl, hydroxycarbamoyl, 5-tetrazolyl orhydroxymethyl; R₁ ^(a) and R₂ ^(a) are hydrogen; and pharmaceuticallyacceptable salts thereof.

Preferred are the said compounds of formula Id and 5,6,7,8-tetrahydroderivatives thereof wherein the group B-C is directly attached at the5-position of the imidazo[1,5-a]pyridine nucleus.

A particular embodiment thereof relates to the compounds of formula Ie##STR9## wherein B represents phenylene; C represents carboxy, loweralkoxycarbonyl or carbamoyl; and pharmaceutically acceptable saltsthereof.

A further embodiment relates to the 5,6,7,8-tetrahydro derivativesthereof.

The compounds of the instant invention have valuable pharmacologicalproperties. For example, they are useful as inhibitors of aromataseactivity in mammals, and for treating conditions responsive thereof. Forexamples, these compounds inhibit the metabolic conversion of androgensor estrogens. Thus, the compounds of formula I and I* are useful e.g. inthe treatment of gynecomastia, i.e. male breast development, byinhibiting the aromatization of steroids in males susceptible to thiscondition. Moreover, the compounds of formula I and I* are useful e.g.in the treatment of estrogen dependent diseases, for example estrogendependent female breast cancer, especially in postmenopausal females, byinhibiting estrogen biosynthesis. These effects are demonstrable in invitro assay tests or in vivo animal tests using advantageously mammals,e.g. guinea pigs, mice, rats, cats, dogs, or monkeys. The applied dosagemay range between about 0.01 and 50 mg/Kg, preferably between about 0.01to 10 mg/Kg.

The in vitro inhibition of aromatase activity of the compounds of thepresent invention can be demonstrated as follows:

A microsomal fraction is prepared from fresh term human placenta by themethod described by Thompson and Siiteri, J. Biol. Chem., Vol. 249, p.5364 (1974). The microsomal preparation so obtained is lyophilized andstored at -40° C. in a dessicator.

The assay is performed in a total volume of 1 ml of 0.05M potassiumphosphate buffer (pH 7,4) at 37° C. The incubation mixture contains1.135×10⁻⁷ M [4-¹⁴ C]-androstene-3,17-dione (New England Nuclear, SA59.7 mCi/mmole), 2.4×10⁻⁴ M NADPH (Sigma, tetrasodium salt Type III),varying concentrations of the test compound and 226 g/ml of themicrosomal enzyme preparation, which is equivalent to 120 μg ofmicrosomal protein as determined by the method of Lowry et al., J. Biol.Chem., Vol. 193, p. 265 (1951). After 20 minutes of incubation themixture is extracted twice with 7 volumes of ethyl acetate, and thecombined extracts are evaporated to dryness. The resulting residue isseparated by chromatography for 65 minutes on thin-layer platesprecoated with silica gel 60 using a mixture of ethyl acetate withisooctane (70:30 v/v) as solvent system. The radioactive zones of theplate are located, and the estrone peak is identified by comparison withan authentic standard. The corresponding band of silica gel istransferred to counting vials for detection with a liquid scintillationdetector. Neither the substrate concentration nor the NADPH is ratelimiting in this system. The number of counts emitted from estrone iscalculated in the absence of the test compound and for eachconcentration of the test compound. The IC₅₀ values are determinedgraphically as the concentration of the test compound at which thecounts pertaining to the amount of estrone formed is reduced to 50% ofthe control value. IC₅₀ values range from about 10⁻⁶ to about 10⁻⁹ M.

With 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine asrepresentative test compound, an IC₅₀ of 4.5×10⁻⁹ M is obtainedaccording to the method mentioned above.

The in vivo inhibition of aromatase activity of the compounds of thepresent invention can be demonstrated as follows:

Twenty-one-day-old female rats are injected subcutaneously with 10 IUpregnant mare serum gonadotropin (PMS). Two days later the same rats areinjected subcutaneously with 30 IU human chorionic gonadrotropin (hCG).On the day following the hCG treatment the rats are injectedsubcutaneously with either propylene glycol (0.2 ml: p.o.) or withvarious doses of the test compound. One hour later all of the rats aretreated with 2.25 mg 4-androstene-3,17-dione in 0.1 ml oil,subcutaneously. Four hours after the injection of androstenedione therats are killed and their ovaries removed and trimmed free of adheringtissue and stored in pairs at -40° C. To determine the total estrogencontent of the ovaries, 1.5 ml of 0.05M aqueous potassium phosphatebuffer, pH 7.4, and 0.2 ml of 0.1N aqueous sodium hydroxide are added tothe tissues which are then homogenized. The homogenate is extracted with15 ml of diethyl ether, 5 ml aliquots are radioimmunoassayed withantiserum having 100% cross reactivity with estrone, estradiol andestriol. The results are expressed as ng estrogen/pair of ovaries.

When 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine is testedas a representative compound for in vivo inhibition of aromataseactivity according to the in vivo test described, supra, a statisticallysignificant inhibition of estrogen synthesis is obtained at doses of0.1, 0.05, and 0.025 moles/100 g (P<0.05) as shown in the followingTable:

                  TABLE                                                           ______________________________________                                        Suppression of Ovarian Estrogen Content of PMS-hCG Primed                     Rats by 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]-                     pyridine Given 1 Hour Prior to Androstenedione                                (n = 6/group)                                                                 Dose        Mean Ovarian Estrogen Content                                     μmoles/100 g                                                                           ng/pair of Ovaries + S.E.                                         ______________________________________                                        0           1.187 ± 0.044                                                  0.1         0.072 ± 0.003                                                  0.05        0.153 ± 0.013                                                  0.025       0.194 ± 0.031                                                  ______________________________________                                    

Illustrative of the invention, minimal effective doses in vivo foraromatase inhibition (suppression of ovarian estrogen content of femalerats) are:

    ______________________________________                                                        Minimal effective dose                                        Compound of example                                                                           (mg/kg p.o.)                                                  ______________________________________                                         1               0.0026                                                        3              0.013                                                         17              0.133                                                         31              0.025                                                         32              0.411                                                         33              0.346                                                         ______________________________________                                    

The antitumor activity, especially in estrogen-dependent tumors, can bedemonstrated in vivo e.g. in dimethylbenzanthracene (DMBA)-inducedmammary tumors in female Sprague-Dawley rats [see Proc. Soc. Exp. Biol.Med. 160, 296-301 (1979)]. Compounds of the invention cause regressionof existing tumors and suppress the appearance of new tumors at dailydoses of about 1 to about 20 mg/kg p.o. or less. Illustrative of theinvention, 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine iseffective at a daily dose of about 0.1 mg/Kg p.o. administered to rats.

Surprisingly, while the compounds of the invention are found to beeffective aromatase inhibitors in vitro and in vivo, they apparently aredevoid of cholesterol side-chain cleavage inhibitory activity in vivo,since they do not induce adrenal hypertrophy as verified by endocrineorgan evaluation.

Due to their pharmacological properties as aromatase inhibitors, thecompounds of the invention can be used as medicaments, for example inthe form of pharmaceutical compositions, for the treatment of conditionsresponsive to aromatase inhibition, such as hormonal diseases, e.g.estrogen dependent tumours, especially mammary carcinoma, and anomalies,e.g. gynecomastia, in mammals, including man.

Compounds of the invention also demonstrate activity as thromboxanesynthetase inhibitors. These are thus also useful for treatingconditions responsive to thromboxane synthetase inhibition in mammals,e.g. for the treatment of cardiovascular disease such as thrombosis andthromboembolisms.

Thromboxane synthetase inhibition is demonstrated in vitro or in vivousing advantageously mammals, e.g. guinea pigs, mice, rats, cats, dogs,or monkeys. Said compounds can be administered to them enterally orparenterally, advantageously orally, or subcutaneously, intravenously orintraperitioneally, for example, within gelatin capsules, or in the formof starchy suspensions or aqueous solutions respectively. The applieddosage may range between about 1.0 and 50 mg/kg/day.

The in vitro inhibition of the thromboxane synthetase enzyme can bedemonstrated, analogous to the method of Sun, Biochem. Biophys. Res.Comm. 74, 1432 (1977); the testing procedure is as follows:

¹⁴ C-arachidonic acid is incubated with an enzyme preparation consistingof solubilized and partially purified prostaglandin cyclo-oxygenase fromsheep seminal vesicles and a crude microsomal preparation of thromboxanesynthetase from lysed hyman platelets. The test compound (dissolved inbuffer, or if necessary, in a small amount of ethanol) is added to theincubation medium. At the end of the incubation period (30 minutes),Prostaglandin E₂ (PGE₂) is reduced to a mixture of Prostaglandin F₂ αand F₂ β (PGF₂ α+β) by addition of sodium borohydride. The radioactiveproducts and excess substrate are extracted into ethyl acetate; theextract is evaporated to dryness; the residue is dissolved in acetone,spotted on thin-layer plates and chromatographed in the solvent systemtoluene:acetone:glacial acetic acid (100 volumes:100 volumes:3 volumes).The radioactive zones are located; those corresponding to Thromboxane B₂(T×B₂) and PGF₂ α+β are transferred to liquid scintillation vials andcounted. The ratio of counts for T×B₂ /PGF₂ α+β is calculated for eachconcentration of test compound and IC₅₀ values are determinedgraphically as the concentration of test compound at which the ratio ofT×B₂ /PGF₂ α+β is reduced to 50% of the control value.

The inhibition of the synthesis and the reduction of plasma levels ofthromboxane is determined in vivo on administration to rats in thefollowing manner (as adapted from the procedures described by Tai et al.in Anal. Biochem. 87: 343, 1978 and by Salmon in Prostaglandins 15: 383,1978):

Rats are dosed with vehicle or test drug and injected intravenously withionophore A23187 (0.5 mg/kg) two hours later. Blood is collected foranalysis 2 minutes after the ionophore injection. A single aliquot ofeach plasma sample is assayed for thromboxane B₂ and another aliquot for6-keto-PGF₁ α, the stable metabolites of thromboxane A₂ and prostacyclin(PGI₂) respectively, by radioimmunoassay.

Illustrative of thromboxane synthetase inhibitory activity,5-(p-carboxyphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine has an IC₅₀of about 9×10⁻⁷ M for thromboxane synthetase inhibition in vitro.

Particularly preferred as thromboxane synthetase inhibitors are thecompounds of the invention wherein R₁ represents carboxy or functionallymodified carboxy.

Particularly preferred as aromatase inhibitors are the compounds of theinvention wherein R₁ represents cyano or halogen.

Compounds of formula I or I*, comprising the compounds of formula Ia andIb, are prepared by processes known per se, preferably by

(a) cyclising a compound of formula II ##STR10## or the 4,5-dihydroderivatives thereof, in order to obtain a compound of formula I or a7,8-dihydro derivative thereof respectively, or

(b) cyclising a compound of formula III ##STR11## wherein R₂ may beattached to any of the carbon atoms indicated inclusive the carbonylcarbon, in order to obtain a 7,8-dihydro derivative of a compound offormula I wherein the substituent C₆ H₄ --R₁ is attached to the5-position, or

(c)/f) converting in a compound of formula IV or VII ##STR12## or in a7,8-dihydro derivative of formula IV, wherein R₁ ' is a group that canbe converted to the cyano group, R₁ ' to cyano, in order to obtain acompound of formula I, a 7,8-dihydro derivative thereof, or a compoundof formula I* respectively, wherein R₁ represents cyano, or

(d) cyclising a compound of formula V ##STR13## wherein at least one ofthe radicals R₂ ' and R₂ " is hydrogen and the other represents aradical R₂ as defined under formula I*, and X₁ is a leaving group, andR₂ ' may be attached to any of the carbon atoms indicated, in order toobtain a compound of formula I*, wherein the substituent C₆ H₄ --R₁ isattached to the 5-position; or X₁ represents ═CH--COOH or a loweralkylester thereof, R₂ ' is hydrogen and R₂ " is as defined underformula I*, in order to obtain a compound of formula I*, wherein thesubstituent C₆ H₄ --R₁ is attached to the 5-position and the 6-positionis substituted by carboxymethyl or lower alkoxycarbonylmethyl, or

(e) cyclising a compound of formula VI ##STR14## wherein thesubstituents C₆ H₄ --R₁ and R₂ may be attached to any of the carbonatoms indicated, either both radicals to the same carbon atom or todifferent carbon atoms, R_(o) is a NH protecting group or hydrogen, andX₂ is a leaving group, in order to obtain a compound of formula I*; or

(g) cyclising a compound of formula IX ##STR15## wherein thesubstituents C₆ H₄ --R₁ and R₂ may be attached to any of the carbonatoms indicated inclusive the carbonyl carbon, either both radicals tothe same carbon atom or to different carbon atoms, optionally underreductive conditions, in order to obtain a 7,8-dihydro derivative of acompound of formula I or, in case of reductive conditions, a compound offormula I*, or

(h) decarboxylating a compound analogous to formula I, or a 7,8-dihydroderivative thereof, or a compound analogous to formula I*, each of whichcontaining an additional carboxy group in 1- or 3-position, in order toobtain a compound of formula I, a 7,8-dihydro derivative thereof, or acompound of formula I* respectively; wherein in the above startingmaterials of the formulae II to VII and IX the symbols n, R₁ and R₂ havethe meanings given under formulae I and I* respectively; and/or, ifdesired, reducing a compound of formula I, or a 7,8-dihydro derivativethereof to the corresponding 5,6,7,8-tetrahydro derivative of formula I*optionally with simultaneous reduction of the substituent(s) R₁ and/orR₂ into (an)other group(s) R₁ and/or R₂ ; and/or, if desired,decarboxylating a compound of formula I*, wherein R₂ is carboxy, inorder to obtain a compound of formula I* wherein R₂ is hydrogen; and/or,if desired, converting a compound obtained into another compound of theinvention and/or converting a salt obtained into the free compound orinto another salt and/or converting a free compound into a salt and/orseparating a mixature of isomers or racemates obtained into the singleisomers or racemates and/or resolving an enantiomeric mixture, such as aracemate, into the optical isomers.

The compounds of the formulae Ia or Ib are prepared by the followingprocess preferably by

(a) cyclizing a compound of the formula IIa ##STR16## wherein R₁ is asdefined above under formula Ia, or the 4,5-dihydro derivative thereof,under acidic conditions, in order to obtain a compound of formula Ia ora 7,8-dihydro derivative thereof, or

(b) for the preparation of the 7,8-dihydro derivative of a compound offormula Ia, cyclizing a compound of the formula IIIa ##STR17## whereinR₁ is as defined above under formula Ia, under basic conditions, or

(c) converting in a compound of the formula IVa ##STR18## wherein R₁ 'is a group or radical that can be converted to the cyano group, or inthe 7,8-dihydro derivative thereof, R₁ ' to cyano, in order to obtain acompound of formula Ia, or

(d) cyclizing a compound of the formula Vb ##STR19## wherein R₁ and R₂are as defined above under formula Ib and X₁ is a leaving group, in thepresence of a base, in order to obtain a compound of formula Ib, or

(e) cyclizing a compound of the formula VIb ##STR20## wherein R₁ and R₂are as defined above under formula Ib and X₂ is a leaving group, in thepresence of a base, in order to obtain a compound of formula Ib, or

(f) converting in a compound of the formula VIIb ##STR21## wherein R₁ 'is a group or radical that can be converted to the cyano group, andwherein R₂ is as defined above under formula Ib, the group R₁ ' tocyano, in order to obtain a compound of formula Ib, wherein R₁ is cyano;and/or, if desired, reducing a compound of the formula Ia, or the7,8-dihydro derivative thereof with hydrogen in the presence of ahydrogenation catalyst to the corresponding 5,6,7,8-tetrahydroderivative of the formula Ib, and/or, if desired, converting a compoundobtained into another compound of the invention and/or converting a saltobtained into the free compound or into another salt and/or converting afree compound having a salt-forming group into a salt and/or separatinga racemic mixture obtained into the individual enantiomers.

Further processes for the preparation of compounds of the formulae Ia orIb are e.g.:

(a) modification of process (e) wherein compounds of formula VIb areused wherein the free NH group is protected by a NH protecting group asdefined below, or

(g) cyclising a compound of formula IXb ##STR22## optionally underreductive conditions, in order to obtain a 7,8-dihydro derivative of acompound of formula Ia or, in case of reductive conditions, a compoundof formula Ib, or

(h) decarboxylating a compound analogous to formula Ia, or a 7,8-dihydroderivative thereof, or a compound analogous to formula Ib, each of whichcontaining an additional carboxy group in 1- or 3-position, in order toobtain a compound of formula Ia, a 7,8-dihydro derivative thereof, or acompound of formula Ib respectively.

Process (a):

The cyclization of the formylamino compound of the formula II or IIa isadvantageously carried out under conditions such as described for thecyclization of 6-methyl-2-methylaminopyridine to5-methylimidazo[1,5-a]pyridine in J. Org. Chemistry 40, 1210 (1975).Said cyclization under acid conditions may be achieved advantageouslywith a Lewis acid, such as polyphosphoric acid, phosphorous oxychlorideor polyphosphate ester.

Process (b):

The cyclization of the formyl compound of the formula III or IIIa iscarried out e.g. under basic conditions. The base employed in thisprocess is any base that readily accepts protons, for example an amine,e.g. a tertiary amine such as a tri-lower alkylamine, e.g.trimethylamine or triethylamine, a cyclic tertiary amine such asN-methylmorpholine, a bicyclic amidine, e.g. a diazabicycloalkene, suchas 1,5-diazabicyclo[4.3.0]non-5-ene or1,5-diazabicyclo[5.4.0]undec-5-ene (DBU), or is, for example, a base ofthe pyridine type, e.g. pyridine. A suitable base is also an inorganicbase, for example an alkali metal hydroxide or alkaline earth metalhydroxide, e.g. sodium, potassium or calcium hydroxide. A preferred baseis an alcoholate, for example an alkali metal alcoholate, e.g. sodium orpotassium methylate, ethylate or tert-butylate.

The cyclization according to processes (a) and (b) is generally carriedout in organic inert solvents, such as suitable alcohols, such asmethanol, ethanol or isopropanol, ketones, such as acetone, ethers, suchas dioxan or tetrahydrofuran, nitriles, such as acetonitrile,hydrocarbons, such as benzene or toluene, halogenated hydrocarbons, suchas methylene chloride, chloroform or carbon tetrachloride, esters, suchas ethyl acetate, or amides, such as dimethylformamide ordimethylacetamide, and the like. The reaction temperature is betweenroom temperature and the boiling temperature of the reaction mixture,preferably between 60° C. and the boiling temperature of the reactionmixture. Furthermore, the cyclization is preferably carried out under aninert gas atmosphere, especially a nitrogen atmosphere.

Process (c)/(f):

A group or radical R₁ ' in a compound of the formula IV, IVa, VII orVIIb, which can be converted into the --CN group, is, for example,hydrogen, esterified hydroxy, for example halo, especially chloro,bromo, or iodo, or a sulfonyloxy group, for examplep-toluenesulfonyloxy, benzenesulfonyloxy or mesyloxy, sulfo, amino,carboxy, carboxy in the form of a functional derivative, for examplecarbamoyl, lower alkylcarbamoyl, for example t-butylcarbamoyl, orhaloformyl, for example chloro- or bromoformyl, formyl, a formyl groupin the form of a functional derivative, for example hydroxyiminomethyl,or a halomagnesium group, for example iodo-, bromo- or chloromagnesium.

Compounds of the formula I, Ia, I* or Ib, wherein R₁ is cyano, can beobtained, for example, by carrying out the following conversions:

The conversion of a compound of the formula IV, IVa, VII or VIIb whereinR₁ ' is hydrogen, to a compound of the formula I, Ia, I* or Ib isperformed e.g. according to the known method of C. Friedel, F. M. Craftsand P. Karrer by reacting with cyanogen chloride (ClCN) or bromide oraccording to the method of J. Houben and W. Fisher, by reacting withe.g. trichloroacetonitrile. Advantageously, the standard catalystaluminium chloride is used in these reactions and hydrogen chloride orhydrogen bromide is split off, which can be removed from the reactionmixture after addition of a base, preferably an amine, for exampletriethylamine or pyridine.

The conversion of a compound of the formula IV, IVa, VII or VIIb,wherein R₁ ' is halo, for example chloro, bromo or iodo, to a compoundof the formula I, Ia, I* or Ib is performed by using e.g. a cyanidesalt, especially sodium or potassium cyanide or, preferably, copper(I)cyanide. Preferred solvents for this reaction are pyridine, quinoline,dimethylformamide, 1-methyl-2-pyrrolidinone and hexamethylphosphorictriamide. High temperatures, especially reflux temperatures of thereaction mixture are preferred.

The conversion of a compound of the formula IV, IVa, VII or VIIb,wherein R₁ ' is a sulfonyloxy group, for example p-toluenesulfonyloxy,benzenesulfonyloxy or mesyloxy, to a compound of the formula I, Ia, I*or Ib is performed e.g. by reaction with an alkali metal cyanide,preferably sodium or potassium cyanide. High temperatures, especiallythe reflux temperature of the reaction mixture, are preferred.

The conversion of a compound of the formula IV, IVa, VII or VIIb,wherein R₁ ' is amino, to a compound of the formula I, Ia, I* or Ibproceeds over several steps. Firstly, a diazonium salt is formed e.g. byreaction of the amino compound with an alkali nitrite salt, preferablypotassium nitrite. The diazonium salt can be reacted according to theknown reaction named after Sandmeyer in situ e.g. with cuprous cyanideor a cyanide complex with labile cyano groups, preferably potassiumcuproammonium cyanide, or with catalytic amounts of freshly precipitatedcopper powder in the presence of an alkali metal cyanide, for examplesodium or potassium cyanide. This reaction is referenced in detail e.g.in Houben-Weyl, Methoden der Organischen Chemie, Thieme Stuttgart 1952,Vol. VIII.

A carboxy group R₁ ' can be coverted to cyano e.g. by reaction withchlorosulfonylisocyanate according to the method of R. Graf, Angew.Chem. 80, 183 (1968). Dimethylformamide is the preferred solvent, carbondioxide is evolved and the chlorosulfonic acid-dimethylformamideaddition salt is precipitated in this reaction.

The conversion of a compound of the formula IV, IVa, VII or VIIb,wherein R₁ ' is a carboxy group in the form of a functional derivative,for example carbamoyl, lower alkylcarbamoyl, for examplet-butylcarbamoyl, to a compound of the formula I, Ia, I* or Ib isperformed e.g. with a strong dehydrating agent, such as phosphoruspentoxide, phosphoryl chloride, thionyl chloride, phosgene or oxalylchloride.

A haloformyl (=halocarbonyl) group R₁ ', for example chloro- orbromoformyl, is reacted with ammonia or a primary or secondary amine,for example methyl- or dimethylamine. The amide thus obtained isconverted to the nitrile of the formula I, Ia, I* or Ib, optionally insitu, with the dehydrating agents mentioned above, for examplephosphorous pentachloride in case of the unsubstituted amide orphosphoryl chloride in case of a mono- or di-lower alkylated amide.

The dehydration can be preferably carried out in the presence of asuitable base. A suitable base is, for example, an amine, for example atertiary amine, for example tri-lower alkylamine, for exampletrimethylamine, triethylamine or ethyl diisopropylamine, or N,N-di-loweralkylaniline, for example N,N-dimethylaniline, or a cyclic tertiaryamine, for example a N-lower alkylated morpholine, for exampleN-methylmorpholine, or is, for example, a base of the pyridine type, forexample pyridine or quinoline.

The conversion of a formyl group to a cyano group is carried out e.g. byconverting the formyl group to a reactive functional derivative, forexample a hydroxyiminomethyl group, and converting this group to cyanoby a dehydrating agent. A suitable dehydrating agent is one of theinorganic dehydrating agents mentioned above, for example phosphorouspentachloride, or, preferably, the anhydride of an organic acid, forexample the anhydride of a lower alkane carboxylic acid, for exampleacetic acid anhydride.

The conversion of the formyl group to hydroxyiminomethyl is carried outby reacting a compound of formula IV, IVa, VII or VIIb, wherein R₁ ' isformyl, e.g. with an acid addition salt of hydroxylamine, preferably thehydrochloride.

A compound of the formula IV, IVa, VII or VIIb, wherein R₁ ' is formyl,can be converted directly to a compound of the formula I, Ia, I* or Ib,e.g. by reaction with O,N-bis-(trifluoroacetyl)hydroxylamine in thepresence of a base, for example pyridine, according to the method of D.T. Mowry, Chem. Rev. 42, 251 (1948).

The conversion of a compound of the formula IV, IVa, VII or VIIb,wherein R₁ ' is a halomagnesium group, for example, iodo-, bromo-, orchloromagnesium, to a compound of the formula I, Ia, I* or Ib, isperformed e.g. by reacting the magnesium halide with cyanogen halide ordicyanogen. Magnesium halide, for example magnesium chloride, ormagnesium cyanohalide, for example magnesium cyanochloride, is producedduring this reaction. The "Grignard" compound, wherein R₁ ' is ahalomagnesium group, is prepared in a conventional manner, for exampleby reacting a compound of the formula IV, IVa, VII or VIIb, wherein R₁ 'is halo, for example chloro, bromo or iodo, with magnesium, e.g. in dryether.

Unless stated otherwise, the conversion of a compound of the formula IV,IVa, VII or VIIb to a compound of the formula I, Ia, I* or Ib ispreferably carried out in an inert, preferably anhydrous, solvent orsolvent mixture, for example in a carboxylic acid amide, for example aformamide, for example dimethylformamide, a halogenated hydrocarbon, forexample methylene chloride, carbon tetrachloride or chlorobenzene, aketone, for example acetone, a cyclic ether, for exampletetrahydrofuran, an ester, for example ethyl acetate, or a nitrile, forexample acetonitrile, or in mixtures thereof, optionally in the presenceof an alcohol, for example methanol or ethanol, or water, optionally atreduced or elevated temperature, for example in a temperature range fromapproximately -40° C. to approximately +100° C., preferably from roomtemperature to the boiling temperature of the reaction mixture andoptionally under inert gas atmosphere, for example nitrogen atmosphere.

Process (d):

In a starting material of the formula V or Vb, a leaving group X₁ ispreferably esterified hydroxy, for example lower alkanoyloxy, forexample acetoxy, or mesyloxy, benzenesulfonyloxy or toluenesulfonyloxy,or, especially, halogen, for example chlorine or bromine.

A suitable base is, for example, an alkali metal or alkaline earth metalhydroxide, e.g. a sodium, potassium or calcium hydroxide, a bicyclicamidine, for example 1,5-diazabicyclo[5.4.0]undec-5-ene, preferably analcoholate, for example sodium or potassium methylate, ethylate ortert-butylate, an alkali metal amide, such as lithium diisopropylamide,or an alkali metal hydride, such as sodium hydride. If R₂ representsfree or functionally modified carboxy or acyl, the reaction isremarkably facilitated and weaker bases, as for example tertiary amines,such as tri-lower alkylamines, e.g. triethylamine, can be used.

The cyclisation is carried out in an aprotic organic solvent, forexample in an ether, for example diethyl ether, dioxan ortetrahydrofuran, or ketone, for example acetone, an amide, for exampledimethylformamide or hexamethylphosphoric acid triamide, or in a mixturethereof, optionally also in a mixture of the mentioned solvents with analkane, for example n-hexane or petroleum ether. The reactiontemperature is between approximately -50° and 50° C., preferably between-10° and room temperature. The reaction is preferably carried out underan inert gas atmosphere, for example an argon or nitrogen atmosphere.

Process (e):

In a starting material of the formula VI or VIb, a leaving group X₂ ispreferably defined as a leaving group X₁ of process (d). The cyclisationis carried out preferably by using a base, such as a tertiary amine asdefined above, e.g. triethylamine, or even using no base at all. NHprotecting (or blocking) groups R_(o) are preferably tri-loweralkylsilyl, such as trimethylsilyl, lower alkanoyl, such as acetyl,dialkylcarbamoyl, such as dimethylcarbamoyl, or triphenylmethyl.

Process (g):

The non-reductive reaction is preferably performed in the presence of anacidic catalyst, e.g. p-toluenesulfonic acid. The reductive aminationreaction is e.g. performed with hydrogen in the presence of an usualhydrogenation catalyst, such as Raney nickel, platinum or palladium oncharcoal, or with a hydrogen-supplying agent, e.g. sodiumcyanoborohydride.

Process (h):

The decarboxylation reaction can be performed with usual decarboxylationmeans, e.g. acids, such as hydrochloric acid, preferably at elevatedtemperatures.

Subsequent Reactions

A compound of the formula I, Ia, Id or Ie can be converted to ahydrogenated derivative of formula I*, the corresponding5,6,7,8-tetrahydro derivatives, e.g. of the formula Ib wherein R₂ ishydrogen, by reduction, e.g. with hydrogen in the presence of ahydrogenation catalyst, e.g. palladium, under acid conditions, forexample in a mineral acid, for instance hydrochloric acid, in an inertsolvent, e.g. ethanol or ethyl acetate.

Furthermore, compounds of formula I* or Ib wherein R₂ is carboxy, can bedecarboxylated in order to obtain another compound of formula I* or Ibwherein R₂ is hydrogen using usual decarboxylation procedures, e.g.those described above for process (h). In said compounds of formula I*,the carboxy substituent R₂ is preferably bonded to the same carbon atomas the substituent C₆ H₄ --R₁.

A compound of formula I* in which the carbon atom adjacent to the ringjunction nitrogen is monosubstituted by C₆ H₄ --R₁, e.g. a compound offormula Ib or Ic wherein R₂ represents hydrogen, can be furthersubstituted on the same carbon atom with groups represented by R₂ bycondensation under basic conditions with a reactive derivative of R₂,for example, a lower alkyl halide, an aryl-lower alkyl halide or a loweralkyl disulfide. Suitable bases comprise an alkali metal alkoxide, suchas potassium t-butoxide, an alkali metal amide, such as lithiumdiisopropylamide, or an alkali metal hydride, such as sodium hydride.

Preparation of the Intermediates

Compounds of the formula II and IIa are known or if they are novel, theycan be prepared according to known methods, for example by reacting acompound of the formula VIII or VIIIa ##STR23## wherein R₁ and R₂ are asdefined above under formula I or Ia, with formic acid or a reactive,functional derivative thereof, e.g. formic acetic anhydride.

Compounds of the formula III and IIIa are prepared e.g. by reacting acompound of formula V, wherein X₁ is hydroxy, n denotes 2, R₂ ' is asdefined under formula V and represents preferably hydrogen, and R₂ " ishydrogen, or a compound of formula Vb, wherein X₁ is hydroxy and R₂ ishydrogen, with e.g. dimethylsulfoxide in the presence of dehydratingagents, for example acid anhydrides, for example anhydrides of organiccarboxylic acids, such as aliphatic or aromatic carboxylic acids ordicarboxylic acids, for example anhydrides of lower alkanecarboxylicacids, especially acetic acid anhydride, mixed anhydrides of loweralkane carboxylic or dicarboxylic acids with mineral acids, for exampleacetyl- or oxalylchloride, as well as anhydrides of inorganic acids,especially of phosphoric acid, such as phosphorus pentoxide. The aboveanhydrides, above all of organic carboxylic acids, for example oxalylchloride, are preferably used in an approximately 1:1 mixture withdimethyl sulfoxide. Further dehydrating or water-absorbing agents arecarbodiimides, above all dicyclohexylcarbodiimide, as well asdiisopropylcarbodiimide, or keteneimides, for examplediphenyl-N-p-tolylketeneimine; these reagents are preferably used in thepresence of acid catalysts, such as phosphoric acid or pyridiniumtrifluoroacetate or pyridinium phosphate. Sulfur trioxide can also beused as a dehydrating or water-absorbing agent, in which case it iscustomarily employed in the form of a complex, for example withpyridine. A base is subsequently added, preferably a base which has beenmentioned above under process (c), for example triethylamine.

The compounds of the formula IV and IVa are prepared preferablyanalogous to process (a) mentioned above.

Compounds of the formula V and Vb are known or if they are novel, theycan be prepared according to known methods, for example by reactinganother compound of the formula V or Vb, wherein X₁ is hydroxy andwherein both R₂ ' and R₂ " are, or R₂ is, preferably hydrogen, with ahalogenating agent or by esterifying the hydroxy group with a reactivefunctional derivative of a sulfonic acid or carboxylic acid. Saidreaction with a halogenating agent, such as thionyl chloride orphosphorous pentachloride, is carried out in a manner analogous to thehalogenation process as described in U.S. Pat. No. 4,089,955. Saidreaction with a reactive functional derivative of a sulfonic orcarboxylic acid, for example a mixed anhydride with a mineral acid, forexample mesylchloride, benzenesulfonyl chloride orp-toluenesulfonylchloride, or acetyl chloride, is carried out by knownesterification methods.

Compounds of the formula VI and VIb are known or if they are novel, theycan be prepared according to known methods, for example by reactinganother compound of the formula VI or VIb, wherein X₂ is hydroxy, R₁ andR₂ are as defined above under formula I* or Ib, and the imidazole NHgroup is optionally protected by a conventional amino protecting group,e.g. tri-lower alkylsilyl, such as trimethylsilyl, with a halogenatingagent or by esterifying the hydroxy group with a reactive, functionalderivative of a sulfonic acid or a carboxylic acid. R₂ is preferablylower alkyl and especially hydrogen. Said halogenation reaction iscarried out analogously to the process according to U.S. Pat. No.4,089,955. Said reaction with a reactive, functional derivative of asulfonic or carboxylic acid, for example a mixed anhydride with amineral acid, for example mesylchloride, benzenesulfonyl chloride orp-toluenesulfonylchloride, or acetyl chloride, is carried out by knownesterification methods.

The compounds of the formula VII or VIIb are prepared preferablyanalogous to processes (d) and (e), and also (g) and (h), mentionedabove.

Compounds of the formula VIII or VIIIa are known or if they are novel,they can be prepared according to known methods, for example byhydrogenation of a compound of the formula XV or XVa ##STR24## whereinR₁ and R₂ are as defined above under formula I or Ia.

The hydrogenation is preferably carried out in the presence of acatalyst, for example platinum or palladium on charcoal, in the presenceof a mineral acid, for example hydrochloric acid.

Compounds of the formula V or Vb, wherein X₁ is hydroxy, are known or ifthey are novel, they can be prepared according to known methods, forexample by reacting a compound of the formula XVII or XVIIa ##STR25##wherein n and R₂ ' are defined as n and R₂ under formula I*, R_(o) is aNH blocking group as defined above, for example di-lower alkylatedcarbamoyl, such as dimethylcarbamoyl, and the hydroxy group is protectedby a conventional hydroxy protecting group, for example trimethylsilyl,with a compound of the formula XVIII or XVIIIa ##STR26## wherein R₁ isas defined under formula I or Ia, R₂ is as defined under formula Ib,preferably hydrogen, R₂ " is defined as R₂ under formula I*, and X₃ is aleaving group, for example esterified hydroxy, for example halogen, forexample chlorine or bromine, or sulfonyloxy, for example mesyloxy orp-toluenesulfonyloxy.

Compounds of the formula VI and VIb, wherein X₂ is hydroxy, R₂preferably is lower alkyl and especially hydrogen and the radical C₆ H₄--R₁ is bonded to the same carbon atom as the group X₂, are known or ifthey are novel, they can be prepared according to known methods forexample by reacting a compound of the formula XIX or XIXa ##STR27##wherein n and R₂ are as defined above under formula I* or Ib, and R₂ ispreferably lower alkyl and especially hydrogen, in formula XIX it beingpossible for the group R₂ to substitute any of the carbon atomsindicated inclusive the carbonyl carbon, and wherein R_(o) ' representspreferably a conventional NH protecting group as defined above, e.g.tri-lower alkylsilyl, such as trimethylsilyl, in an organometallic groupreaction with a compound of the formula XX ##STR28## wherein R₁ is asdefined under formula I or Ia.

Compounds of the formula XV and XVa can be prepared e.g. by converting acompound of the formula XXI or XXIa ##STR29## to the N-oxide with anoxidizing agent, e.g. peracetic acid, treating the N-oxide with amethylating agent, e.g. dimethyl sulfate and substituting the 6-positionwith cyanide ion, e.g. by using potassium cyanide.

Compounds of the formulae XVII-XXI, XVIIa-XIXa and XXIa are known or maybe prepared using conventional chemical methodology.

Compounds of formula IX and IXb can be prepared e.g. by the followingsequence of transformations: Oxidation of a compound of formula XIX--orformula XIXa, wherein R₂ is hydrogen--with usual oxidations means, e.g.KMnO₄, yields the corresponding acid which optionally can be convertedfurther to the corresponding lower alkylester. Reacting the latter--orthe free acid--with a compound of formula XX, or a suitableorganometallic equivalent thereof, and splitting off the NH protectinggroup leads to compounds of formula IXb and IX, in the latter of whichthe substituent C₆ H₄ --R₁ is bonded to the carbonyl carbon.

Compounds of formula VI and IX, wherein the substituent C₆ H₄ --R₁ isnot bonded to the same carbon atom as the group X₂ or to the carbonylcarbon respectively, can be obtained e.g. from compounds analogous toformula XVII containing in addition a substituent C₆ H₄ --R₁ in the sidechain according to well-known procedures, e.g. by esterification of thehydroxy group or its oxidation to formyl respectively. The startingmaterials analogous to formula XVII can be prepared using conventionalchemical methodology.

Starting materials for process (h) containing a carboxy group in 3- or1-position of the bicyclic ring system can be obtained e.g. by reactinga compound of formula VIII or VIIIa, or a compound analogous to theseformulae containing an additional carboxy group in α-positionrespectively, with e.g. oxalic acid lower alkylester halide, such asethyl oxalyl chloride, or with a formic acid derivative, e.g. formicacetic anhydride, and subsequent ringclosure achieved by a Lewis acid,e.g. phosphorous oxychloride, respectively.

If any intermediates mentioned contain interfering reactive groups, e.g.carboxy, hydroxy, amino, sulfo or mercapto groups, such asadvantageously be temporarily protected at any stage with easilyremovable protecting groups. The choice of protecting groups for aparticular reaction depends on several factors, e.g. the nature of thefunctional group to be protected, the structure and stability of themolecule of which the substituent is the functional group, and thereaction conditions. Protecting groups that meet these conditions andtheir introduction and removal are known to the art and are described,for example, in J. F. W. McOmie, "Protective Groups in OrganicChemistry", Plenum Press, London, New York 1973. Thus, carboxy groupsand also sulfo groups, are protected, for example, in esterified form,e.g. as unsubstituted or substituted lower alkyl esters, such as methylor benzyl esters, it being possible for such ester groupings to beremoved easily under mild conditions, especially alkaline conditions.Amino- and hydroxy-protecting groups that can be removed under mildconditions are for example acyl radicals, such as lower alkanoyloptionally substituted by halogen, e.g. formyl or trichloroacetyl, ororganic silyl, e.g. tri-lower alkylsilyl, such as trimethylsilyl.

Salts of compounds of the invention can be manufactured in a mannerknown per se. Thus, they can be formed e.g. in accordance with themethods described in the Examples. Acid addition salts of compounds ofthe invention are obtained in a customary manner, for example bytreating the free compound with an acid or a suitable anion exchangereagent. Salts can be converted into the free compounds in a customarymanner, for example by treating the acid addition salt with a suitablebasic agent, for example an alcoholate, e.g. potassium-tert-butoxide. Onthe other hand, compounds of the invention containing acidic groups,e.g. carboxy, can be converted into salts in a manner known per se bytreating with a base, e.g. an alkali metal hydroxide or alkoxide, analkali metal or alkaline-earth metal salt, e.g. sodium hydrogencarbonate, ammonia or a suitable organic amine. The free compounds canbe obtained by treating such salts with an acid. In view of the closerelationship between the free compounds and the compounds in the form oftheir salts, whenever a compound is referred to in this context, acorresponding salt is also intended, provided such is possible orappropriate under the circumstances.

Depending on the choice of starting materials and methods, the newcompounds may be in the form of one of the possible isomers or mixturesthereof, for example, depending on the presence of chiral carbon atoms,as optical isomers, such as antipodes, or as mixtures of opticalisomers, such as racemates, or as mixtures of diastereoisomers.

Resulting mixtures of diastereoisomers can be separated on the basis ofthe physicochemical differences of the constituents, for example bychromatography and/or fractional crystallisation.

Resulting racemates can furthermore be resolved into the opticalantipodes by known methods, for example by chromatography using anoptically active stationary phase, by recrystallisation from anoptically active solvent, by means of microorganisms or by reacting anacidic intermediate or final product with an optically active base thatforms salts with the racemic acid, and separating the salts obtained inthis manner, for example on the basis of their different solubilities,into the diastereoisomers, from which the antipodes can be liberated bythe action of suitable agents. Basic racemic products can likewise beresolved into the antipodes, for example, by separation ofdiastereoisomeric salts thereof, e.g. by the fractional crystallizationof d- or l-tartrates.

The above-mentioned reactions are carried out according to standardmethods, in the presence or absence of diluents, preferably such as areinert to the reagents and are solvents thereof, of catalysts, condensingor said other agents respectively and/or inert atmospheres, at lowtemperatures, room temperature or elevated temperatures, e.g. in atemperature range from -20° to +200° C., preferably at the boiling pointof the solvents used, and at atmospheric or super-atmospheric pressure.The preferred solvents, catalysts and reaction conditions are set forthin the appended illustrative examples.

The compounds, including their salts, can also be obtained in the formof their hydrates, or include other solvents used for theircrystallization.

The invention further includes any variant of the present processes, inwhich an intermediate product obtainable at any stage thereof is used asstarting material and the remaining steps are carried out, or theprocess is discontinued at any stage thereof, or in which the startingmaterials are formed under the reaction conditions or in which thereaction components are used in the form of their salts or opticallypure antipodes. Mainly those starting materials should be used in saidreactions, that lead to the formation of those compounds indicated aboveas being especially useful. The invention also relates to novel startingmaterials and processes for their manufacture.

The invention further relates to pharmaceutical compositions for enteralor parenteral administration, which compositions comprise atherapeutically effective amount of a compound of the inventionoptionally together with a pharmaceutically acceptable carrier ormixture of carriers. Solid or liquid inorganic or organic substances areused as carriers. Appropriate dosage unit formulations, especially forperoral administration, e.g. tablets or capsules, preferably containabout 5 mg to 200 mg. preferably 5 mg to 100 mg, most preferably about10 to 50 mg, of a compound of the invention, or of a pharmaceuticallyacceptable salt of such a compound which is capable of salt formation,together with pharmaceutically acceptable carriers.

Suitable carriers are in particular fillers such as sugar, for examplelactose, saccharose, mannitol or sorbitol, cellulose preparations and/orcalcium phosphates, e.g. tricalcium phosphate or calcium biphosphate,and also binders such as starch pastes, e.g. maize, corn, rice or potatostarch, gelatin, tragacanth, methyl cellulose and/or, if desired,disintegrators, such as the above mentioned starches, also carboxymethylstarch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a saltthereof such as sodium alginate. Adjuncts are in particular glidants andlubricants, for example silica, talc, stearic acid or salts thereof suchas magnesium stearate or calcium stearate, and/or polyethylene glycol.Dragee cores are provided with suitable coatings which can be resistantto gastric juices, using inter alia concentrated sugar solutions whichmay contain gum arabic, talc, polyvinylpyrrolidinone, polyethyleneglycol and/or titanium dioxide, shellac solutions in suitable organicsolvents or mixtures of solvents or, for the preparation of coatingswhich are resistant to gastric juices, solutions of suitable cellulosepreparations such as acetyl cellulose phthalate orhydroxypropylmethylcellulose phthalate. Dyes or pigments can be added tothe tablets or dragee coatings, for example to identify or indicatedifferent doses of the active ingredient.

Further pharmaceutical compositions for oral administration aredry-filled capsules made of gelatin and also soft sealed capsulesconsisting of gelatin and a plasticiser such as glycerol or sorbitol.The dry-filled capsules can contain the active ingredient in the form ofgranules, for example in admixture with fillers such as lactose, binderssuch as starches and/or glidants such as talc or magnesium stearate, andoptionally stabilisers. In soft capsules, the active ingredient ispreferably dissolved or suspended in suitable liquids, such as fattyoils, paraffin oil or liquid polyethylene glycols, to which stabiliserscan also be added.

Suitable pharmaceutical compositions for rectal administration are e.g.suppositories, which consist of a combination of the active ingredientwith a suppository base. Examples of suitable suppository bases arenatural or synthetic triglycerides, paraffin, polyethylene glycols andhigher alkanols. It is also possible to use gelatin rectal capsuleswhich contain a combination of the active ingredient with a basematerial. Suitable base materials are e.g. liquid triglycerides,polyethylene glycols and paraffins.

Particularly suitable dosage forms for parenteral administration aresuspensions of the active ingredient, such as corresponding oilyinjection solutions or suspensions, for which are used suitablelipophilic solvents or vehicles such as fatty oils, for example sesameoil, or synthetic fatty acid esters, for example ethyl oleate ortriglycerides, or aqueous injection suspensions or solutions whichcontain substances which increase the viscosity, for example sodiumcarboxymethylcellulose, sorbitol and/or dextran, and optionally alsostabilizers.

The pharmaceutical compositions of the present invention are prepared ina manner known per se, for example by conventional mixing, granulating,confectioning, dissolving or lyophilising methods. For example,pharmaceutical compositions for oral administration can be obtained bycombining the active ingredient with solid carriers, optionallygranulating a resulting mixture and processing the mixture ofgranulates, if desired or necessary after the addition of suitableadjuncts, to tablets or dragee cores.

The present invention also relates to a method of inhibiting aromataseactivity in mammals by administering an effective aromatase inhibitingamount of a compound of the invention, e.g. of formula I, I*, Ia, Ib orId or a pharmaceutically acceptable salt thereof, or of a pharmaceuticalcomposition comprising said compound, to a mammal in need thereof.

The present invention is thus also directed to the method of treatmentin mammals of conditions responsive to aromatase inhibition, e.g.gynecomastia and estrogen dependent diseases, e.g. estrogen dependenttumors such as breast carcinoma, by administering an effective aromataseinhibiting amount of a compound of the invention, or of a pharmaceuticalcomposition comprising such compound, to a mammal in need thereof.

A further aspect of the invention relates to a method of inhibitingthromboxane synthetase in mammals and for treating conditions responsiveto thromboxane synthetase inhibition in mammals, by administering aneffective thromboxane synthetase inhibiting amount of a compound of theinvention, or of a pharmaceutical composition comprising said compoundto a mammal in need thereof.

EXAMPLES

The following examples are intended to illustrate the invention and arenot to be construed as being limitations thereon. Temperatures are givenin degrees Centigrade, and all parts wherever given are parts by weight.If not mentioned otherwise, all evaporations are performed under reducedpressure, preferably between about 15 and 100 mm Hg.

EXAMPLE 1 5-(p-Cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinehydrochloride

A solution of 8.1 g of5-(3-chloropropyl)-1-(p-cyanophenylmethyl)-1H-imidazole in 50 ml oftetrahydrofuran is cooled to 0°. To this is added 7.0 g of potassiumt-butoxide as a solid in portions. The mixture is stirred at roomtemperature for 2 h, neutralized with 10% acetic acid and partitionedbetween methylene chloride and water. The organic layer is washed withwater, dried over magnesium sulfate and evaporated to yield an oil whichis dissolved in a small volume of acetone and neutralized with etherealhydrogen chloride. On cooling, the title compound is obtained as a whitesolid, m.p. 201°-203°.

Preparation of the starting materials:

(a) 1-Dimethylcarbamoyl-4-(3-trimethylsilyloxypropyl)-1H-imidazole.

To a suspension of 51.8 g of 4-(3-hydroxy-n-propyl)-1H-imidazole[obtainable according to Il Farmaco, Ed. Sc. 29, 309 (1973)] in 500 mlof acetonitrile 50.0 g of triethylamine is added. To this mixture 48.6 gof dimethylcarbamoyl chloride is added dropwise. When addition iscomplete, the mixture is refluxed for 21 h. The solution is cooled to0°, whereupon there is precipitation of triethylamine hydrochloride. Tothis mixture is added 50.0 g of triethylamine followed by 54.0 g ofchlorotrimethylsilane. After addition is complete stirring is continuedfor 1 h. The mixture is diluted with an equal volume of ether andfiltered. The fitrate is evaporated to an oil which is triturated withether and filtered to remove additional triethylamine hydrochloride.This filtrate is then evaporated to yield the title compound (a) as anoil.

(b) 1-(p-Cyanophenylmethyl)-5-(3-hydroxypropyl)-1H-imidazole.

A solution of 97.0 g of1-dimethylcarbamoyl-4-(3-trimethylsilyloxypropyl)-1H-imidazole and 72.0g of 1-bromomethyl-4-cyanobenzene in 500 ml of acetonitrile is refluxedfor 10 h. The solution is cooled to 0° in an ice bath and ammonia gas isbubbled in for a few minutes. The mixture is then evaporated in vacuo togive a semi-solid which is dissolved in 500 ml of 1N hydrochloric acid.The solution is allowed to stand at room temperature for 15 min and thenis extracted with ether. The pH of the aqueous phase is adjusted to 9with 50% sodium hydroxide solution and the mixture is then extractedwith methylene chloride. The methylene chloride extracts are washed withwater, dried over sodium sulfate and evaporated to give a semi-solidwhich is triturated with cold acetone to yield the title compound (b) asa white solid, m.p. 121°-123°.

(c) 5-(3-Chloropropyl)-1-(p-cyanophenylmethyl)-1H-imidazole.

To a solution of 5.2 g of thionyl chloride in 80 ml of methylenechloride is added 8.4 g of1-(p-cyanophenylmethyl)-5-(3-hydroxypropyl)-1H-imidazole as a solid inportions. The rate of addition is regulated to control the foaming thatoccurs. When addition is complete, the solution is refluxed for 1.5 h,cooled in ice and filtered to obtain the hydrochloride salt of the titlecompound (c) as a buff-colored solid, m.p. 190°-191°. The salt ispartitioned between methylene chloride and saturated sodium bicarbonatesolution. The organic extracts are washed with water, dried over sodiumsulfate and evaporated to yield the free base as an oil.

EXAMPLE 2 5-(p-Cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinehydrochloride

A solution of 2.0 g of4-[4-chloro-4-(p-cyanophenyl)-n-butyl]-1H-imidazole in 50 ml ofchloroform is refluxed for 4 h under nitrogen, cooled and evaporated toyield the title compound.

Preparation of the starting materials:

(a) 4-(3-Formyl-n-propyl)-1-trimethylsilylimidazole.

A solution of 1.82 g of 4-(3-ethoxycarbonylpropyl)-1H-imidazole in 30 mlof tetrahydrofuran under nitrogen is treated with 0.5 g of sodiumhydride (50% oil dispersion) at 0° for 30 min and 1.45 ml oftrimethylsilyl chloride at 0° for 3 h. The reaction mixture is washedwith cold 0.5N sodium bicarbonate solution, dried over sodium sulfateand evaporated to dryness. The oil is redissolved in 100 ml of methylenechloride at -78° under nitrogen and 12.82 ml of diisobutylaluminiumhydride (1.56M) is added dropwise. The reaction mixture is stirred for 5min at -78°, quenched with 1 ml of methanol followed by 10 ml of waterand filtered through Celite®. The organic phase is separated, dried oversodium sulfate and evaporated to yield the title compound (a).

(b)4-[4-(p-tert-Butylaminocarbonylpheyl)-4-hydroxy-n-butyl]-1-trimethylsilylimidazole.

A solution of 6.95 g of p-(tert-butylaminocarbonyl)-bromobenzene isdissolved in 175 ml of tetrahydrofuran at -70° under nitrogen and 20.1ml of a solution of n-butyllithium (2.7M) in hexane is added dropwise.After reacting 30 min, a solution of 5.69 g of4-(3-formyl-n-propyl)-1-trimethylsilylimidazole in 10 ml oftetrahydrofuran is added slowly. The reaction mixture is allowed to warmslowly to room temperature and 20 ml of ammonium chloride is added. Theorganic layer is separated, dried over sodium sulfate and evaporated toyield the title compound (b).

(c) 4-[4-Chloro-4-(p-cyanophenyl)-n-butyl]-1H-imidazole.

A solution of 4.5 g of4-[4-(p-tert-butylaminocarbonylphenyl)-4-hydroxy-n-butyl]-1-trimethylsilylimidazolein 50 ml of thionyl chloride is refluxed for 1 h, cooled and evaporated.The residue is partitioned between methylene chloride and aqueous sodiumbicarbonate solution. The organic phase is separated, dried over sodiumsulfate and evaporated to yield the title compound (c).

EXAMPLE 3 5-(p-Cyanophenyl)imidazo[1,5-a]pyridine.

A solution of 0.1 g of5-(p-tert-butylaminocarbonylphenyl)imidazo[1,5-a]pyridine in 3 ml oftoluene is treated with 40 μl of phosphorus oxychloride at 90° for 5 h.The solvent is evaporated and the residue is redissolved in 30 ml ofchloroform at 0°. An ice-cold ammonium hydroxide solution is added andthe organic phase is separated, dried over sodium sulfate andevaporated. The residue is chromatographed on silica with ethyl acetateto yield the title compound, m.p. 117°-118°.

EXAMPLE 4 5-(p-Ethoxycarbonylphenyl)imidazo[1,5-a]pyridine

A solution of 9.8 g of2-(p-ethoxycarbonylphenyl)-6-formylaminomethylpyridine and 11.15 gphosphorus oxychloride in 26 ml of toluene is heated at 90° for 15 h.The solvent is evaporated and the residue taken up in 50 ml of methylenechloride, cooled to 0° and made basic with excess ice-cold, saturatedammonium hydroxide solution. The organic phase is separated, dried andevaporated. The residual solid is passed through 100 g of silica gelwith ethyl acetate as eluent to yield after crystallization the titlecompound, m.p. 118°-119°.

Preparation of the starting materials:

(a) 6-Cyano-2-(p-ethoxycarbonylphenyl)pyridine.

8.9 ml of 40% peracetic acid is added dropwise to 14.08 g of2-(p-ethoxycarbonylphenyl)pyridine so as to maintain the reactiontemperature between 80° and 85°. After the addition is complete thereaction mixture is heated at 90° for 3 h, and allowed to cool to roomtemperature. The excess peracetic acid is destroyed with aqueous sodiumsulfite solution. The solvent is evaporated and the residue taken up inmethylene chloride and refiltered through Celite®. Evaporation yields2-(p-ethoxycarbonylphenyl)pyridine-N-oxide which is treated with 8.66 gdimethyl sulfate in 62 ml of toluene at 90° for 3 h. The solvent isevaporated and the residue redissolved in an ice-cold mixture of 8 ml ofwater and 9.3 ml of 1N sodium hydroxide. A solution of 13.64 g ofpotassium cyanide in 10 ml of water is added slowly and the reactionmixture is maintained at 0° for 24 h. Extraction with methylenechloride, drying over sodium sulfate and evaporation of solvent yieldsthe title compound (a); IR (CH₂ Cl₂) 2200 cm⁻¹.

(b) 6-Aminomethyl-2-(p-ethoxycarbonylphenyl)pyridine.

16.23 g of 6-cyano-2-(p-ethoxycarbonylphenyl)pyridine is hydrogenated atatmospheric pressure in 254 ml of methanol with 12.9 ml of concentratedhydrochloric acid and 2.63 g of 10% palladium on charcoal until 2 molarequivalents of hydrogen have been consumed. Sodium methoxide (6.9 g) isadded and the catalyst is filtered off. The solvent is evaporated. Theresidue is redissolved in 20 ml of methylene chloride and the salts areremoved by filtration. Evaporation of the solvent yields a solid whichis recrystallized from chloroform to yield the title compound (b), m.p.141°-143°.

(c) 2-(p-Ethoxycarbonylphenyl)-6-formylaminomethylpyridine.

A solution of 0.76 g 6-aminomethyl-2-(p-ethoxycarbonylphenyl)pyridine in10 ml of formic acid is heated at 90° for 15 h. The reaction mixture iscooled to 0°, made basic with excess saturated ammonium hydroxidesolution and extracted with chloroform. The organic extracts are driedand evaporated to yield the title compound (c) which is recrystallizedfrom toluene, m.p. 119.5°-120.5°.

EXAMPLE 5 5-(p-Carboxyphenyl)imidazo[1,5-a]pyridine

A solution of 1.18 g or 5-(p-ethoxycarbonylphenyl)imidazo[1,5-a]pyridinein 10 ml of ethanol and 14 ml of 1N sodium hydroxide solution isrefluxed for 3 h, cooled and evaporated. The residue is partitionedbetween water and ethyl acetate. The aqueous phase is separated andadjusted to pH 5. The solid is filtered, washed with water and dried toyield the title compound, m.p. 308°-310° (dec.).

EXAMPLE 6 5-(p-tert-Butylaminocarbonylphenyl)imidazo[1,5-a]pyridine

To a slurry of 0.4 g of 5-(p-carboxyphenyl)imidazo[1,5-a]pyridine in 40ml of methylene chloride under nitrogen at room temperature, is added 30μl of N,N-dimethylformamide followed by 0.16 ml of oxalyl chloride. Thereaction mixture is stirred until gas evolution is complete and 0.46 mlof tert-butylamine is added dropwise. Stirring is discontinued after 90min and 10 ml of saturated sodium bicarbonate solution is added. Theorganic layer is separated, dried over sodium sulfate and evaporated toyield the title compound, m.p. 128°-131°.

EXAMPLE 7 5-(p-Cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinehydrochloride

A solution of 1.13 g of5-(p-carbamoylphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and 1.0ml of phosphorus oxychloride in 30 ml of chloroform is refluxed for 15h, cooled and evaporated with toluene. The resulting oil is redissolvedin 30 ml of methylene chloride, cooled to 0° and 30 ml of an ice-coldsolution of 50% ammonium hydroxide solution is added. The organic phaseis separated, dried and evaporated to an oil. Filtration through 20 g ofsilica with ethyl acetate yields the free title compound which isdissolved in 20 ml of acetone and treated with 1.2 ml of 3N etherealhydrogen chloride to yield its hydrochloride, m.p. 209°-210°.

EXAMPLE 85-(p-Ethoxycarbonylphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinehydrochloride

A solution of 2.0 g of 5-(p-ethoxycarbonylphenyl)imidazo[1,5-a]pyridinein 120 ml of anhydrous ethanol containing 30 ml of concentratedhydrochloric acid, is hydrogenated with 1.0 g of 10% palladium oncharcoal at 40 psi hydrogen and 60° for 4 h. The catalyst is filteredand the solvent is evaporated to yield a solid which is recrystallizedfrom isopropanol and ether to provide the title compound, m.p.164°-166°.

EXAMPLE 9 5-(p-Carboxyphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A solution of 0.66 g of5-(p-ethoxycarbonylphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine in8.0 ml of ethanol and 8.0 ml 1N sodium hydroxide is refluxed for 3 h,cooled and evaporated. The residue is partitioned between water andethyl acetate. The aqueous phase is adjusted to pH 5 with concentratedsulfuric acid and the solid is filtered and air-dried to yield the titlecompound, m.p. 309°-310° (dec.).

EXAMPLE 105-(p-Carbamoylphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A solution of 5.42 g of5-(p-carboxyphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine in 75 ml ofthionyl chloride is refluxed for 30 min, cooled and evaporated withtoluene. The residue is redissolved in methylene chloride, cooled to 0°and treated with gaseous ammonia until the solution is saturated. Thereaction mixture is stirred for 10 min under an ammonia atmosphere andthe resulting solid is collected by filtration to yield the titlecompound, m.p. 181°-183°. Treatment with a molar equivalent of fumaricacid in ethanol yields the fumarate salt, m.p. 164°-166° (dec.).

EXAMPLE 11 5-(p-Tolyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinehydrochloride

A solution of 0.36 g of 5-(p-hydroxymethylphenyl)imidazo[1,5-a]pyridinein 25 ml of ethanol and 6.4 ml of concentrated hydrochloric acid ishydrogenated with 0.15 g of 10% palladium on charcoal at 40 psi ofhydrogen and 60° for 4 h. The reaction mixture is filtered andevaporated and the residue is partitioned between methylene chloride andsodium bicarbonate solution. The organic phase is dried over sodiumsulfate and evaporated to an oil which is purified by preparative layerchromatography on silica with ethyl acetate. The hydrochloride salt isprepared in acetone with 1.1 molar equivalents of ethereal hydrogenchloride to yield the title compound, m.p. 173°-175°.

EXAMPLE 12 5-(p-Hydroxymethylphenyl)imidazo[1,5-a]pyridine

1 g of 5-(p-ethoxycarbonylphenyl)imidazo[1,5-a]pyridine is dissolved in26 ml of methylene chloride at -78° under nitrogen, and then 6.6 ml ofdiisobutylaluminium hydride in toluene (11.4 mmole) is added dropwise.After stirring for 1 h, 1.5 ml of methanol is added, the cold bath isremoved and 15 ml of water is added. The salts are filtered off, theorganic phase is dried over sodium sulfate and evaporated to yield thetitle compound, m.p. 137°-138°.

EXAMPLE 13 5-(p-Cyanophenyl)-7,8-dihydroimidazo[1,5-a]pyridine

A solution of 0.24 g of1-(p-cyanophenylmethyl)-5-(2-formylethyl)-1H-imidazole in 10 ml ofanhydrous ethanol is refluxed under nitrogen for 2 h with 20 mg ofpotassium tert-butoxide, cooled and evaporated to yield the titlecompound.

Preparation of the starting material:

(a) 1-(p-Cyanophenylmethyl)-5-(2-formylethyl)-1H-imidazole

A solution of 0.14 ml of dimethylsulfoxide in 5 ml of methylene chlorideis cooled to -78° under N₂ and 0.1 ml of oxalyl chloride is addeddropwise. After 30 min, a solution of 0.24 g of1-(p-cyanophenylmethyl)-5-(3-hydroxypropyl)-1H-imidazole in 1 ml ofmethylene chloride and 0.2 ml of dimethylsulfoxide is added slowly. Thereaction mixture is stirred at -78° for 2 h and 1 ml of triethylamine isadded slowly. The reaction mixture is allowed to warm slowly to roomtemperature, diluted with 30 ml of methylene chloride and washed threetimes with 10 ml of water. The organic phase is dried over sodiumsulfate and evaporated to yield the title compound (a) as an oil, NMR(60 MHZ): δ 5.15 (s, 2H), 9.65 (s, 1H).

EXAMPLE 14 5-(p-Cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A solution of 1.6 g of5-(p-cyanophenyl)-7,8-dihydroimidazo[1,5-a]pyridine in 50 ml of ethylacetate is hydrogenated at atmospheric pressure with 0.2 g of 5%palladium on charcoal until the theoretical uptake of hydrogen iscomplete. The catalyst is filtered, and the solvent evaporated to yieldthe title compound, m.p. 117°-118°.

EXAMPLE 15 5-(p-Cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A solution of 54 mg of 5-(p-cyanophenyl)imidazo[1,5-a]pyridinehydrochloride in 5.0 ml methanol is hydrogenated at room temperature andatmospheric pressure for 30 min with 0.1 g of 10% palladium on charcoal.The catalyst is filtered and 0.21 ml of 1N sodium hydroxide is added.The filtrate is evaporated, taken up in 10 ml of methylene chloride andfiltered through Celite®. Evaporation yields an oil which ischromatographed on silica gel with ethyl acetate to yield the titlecompound, m.p. 117°-118°.

EXAMPLE 16 5-(p-Cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A mixture of 85 mg of5-(p-bromophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and 74 mg ofcuprous cyanide in 1 ml of N,N-dimethylformamide is heated undernitrogen at 120° for 11 h. The reaction mixture is cooled, diluted with10 ml of water and extracted with ethyl acetate. The organic extractsare dried over sodium sulfate and evaporated. The resulting oil ischromatographed on silica gel with ethyl acetate to yield the titlecompound, m.p. 117°-118°.

EXAMPLE 17 5-(p-Bromophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A solution of lithium diisopropylamide, prepared at 0° from 0.12 ml ofdiisopropylamine and 0.33 ml of n-butyllithium (2.5M) in 2 ml oftetrahydrofuran under nitrogen, is added to a solution of 0.13 ml ofN,N,N',N'-tetramethyl-ethylenediamine and 0.124 g of1-(p-bromobenzyl)-5-(3-chloropropyl)-1H-imidazole in 2 ml oftetrahydrofuran at -78°. The reaction mixture is stirred for 3.5 h,quenched at -78° with saturated ammonium chloride solution and extractedwith methylene chloride (3×10 ml). The organic extracts are dried oversodium sulfate and evaporated to yield the title compound which ispurified by conversion to the hydrochloride salt, m.p. 216°.

Preparation of the starting materials:

(a) 1-(p-Bromobenzyl)-5-(3-hydroxypropyl)-1H-imidazole.

A solution of 11.2 g of1-dimethylcarbamoyl-4-(3-trimethylsilyloxypropyl)-1H-imidazole and 12.49g of p-bromobenzyl bromide in 110 ml of acetonitrile is refluxed for 24h. The solution is cooled to 0° and ammonia gas is bubbled through thereaction mixture for 5 min. After reacting an additional 45 min at roomtemperature, the solvent is evaporated. The residue is taken up in 100ml of 1N hydrochloric acid and extracted with 50 ml of ether. Theaqueous phase is adjusted to pH 8 and extracted with ethyl acetate (5×50ml). The organic extracts are washed with water, dried over sodiumsulfate and evaporated. The resulting oil is chromatographed on 530 g ofsilica gel with ethyl acetate-methanol:saturated NH₄ OH (90:50:5) toyield the title compound (a) as an oil; NMR; δ 5.00 (s, 2H).

(b) 1-(p-Bromobenzyl)-5-(3-chloropropyl)-1H-imidazole.

1-(p-Bromobenzyl)-5-(3-hydroxypropyl)-1H-imidazole is treated withthionyl chloride analogous to the method described in example (1c) togive the title compound (b).

EXAMPLE 18 5-(p-Cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A solution of 2.01 g of5-(p-formylphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine and 0.96 gof hydrazoic acid in 30 ml benzene is maintained by external cooling atroom temperature, while 0.8 ml of concentrated sulfuric acid is addeddropwise. The reaction mixture is stirred for 2 h and neutralized. Theorganic phase is separated, dried over sodium sulfate and evaporated toyield an oil which is chromatographed on silica gel with ethyl acetateto yield the title compound.

EXAMPLE 195-(p-Hydroxymethylphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A solution of 0.40 g of5-(p-ethoxycarbonylphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine in20 ml of methylene chloride is cooled to -70° under nitrogen and 4.0 mlof a 1.53M diisobutylaluminium hydride solution in toluene is addeddropwise. The reaction mixture is allowed to warm to room temperature,quenched with 3.2 ml of methanol and 15 ml of water and filtered throughCelite®. The layers are separated, the organic one is dried over sodiumsulfate and evaporated to yield the title compound, m.p. 142°-145°.

EXAMPLE 20 5-(p-Formylphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A solution of 0.16 ml of dimethylsulfoxide in 16 ml of methylenechloride is cooled to -70° under nitrogen and 0.17 g of oxalyl chlorideis added dropwise. The reaction mixture is stirred for 30 min and 0.24 gof 5-(p-hydroxymethylphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine in4 ml of methylene chloride is added slowly. The reaction mixture isstirred for 2 h at -70°, 0.8 ml of triethylamine is added dropwise, andthe reaction mixture is allowed to warm slowly to room temperature. Thereaction mixture is diluted with 20 ml of methylene chloride, washedwith water, dried over sodium sulfate and evaporated to yield the titlecompound which is purified by conversion to the furmaric acid salt, m.p.131°.

EXAMPLE 215-(p-Cyanophenyl)-5-methylthio-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinehydrochloride

A solution of lithium diisopropylamide is prepared at 0° under nitrogenfrom 0.6 ml of n-butyllithium (2.5M) and 0.15 g of diisopropylamine in 5ml of dry tetrahydrofuran and is transferred to 0.29 g of5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine in 10 ml oftetrahydrofuran at -78°. The reaction mixture is stirred for 30 min and0.14 g of dimethyl disulfide is added dropwise. Cooling is discontinuedafter 30 min and the reaction mixture is allowed to warm to roomtemperature and quenched with 10 ml of saturated ammonium chloridesolution. The layers are separated and the organic phase is washed withcold 1N hydrochloric acid. The aqueous phase is neutralized andextracted with ethyl acetate. The organic extracts are dried over sodiumsulfate and evaporated to an oil which is chromatographed on silica gelwith 5% isopropanol in ethyl acetate. The resulting oil is redissolvedin acetone and treated with 0.1 ml of 4N ethereal hydrogen chloride toyield the title compound, m.p. 204°-205°.

EXAMPLE 225-(p-Cyanophenyl)-5-ethoxycarbonyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

In a manner analogous to that described in example 21, reaction of5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine with ethylchloroformate yields the title compound.

EXAMPLE 23 5-(p-Cyanophenyl)-5,6,7,8-tetrahydroimidazol[1,5-a]pyridine

A solution of 1.65 g of5-(p-cyanophenyl)-5-ethoxycarbonyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinein 10 ml of methanol containing 0.2 g of sodium hydroxide is stirred for3 h at room temperature and 5 ml of 1N hydrochloric acid is added. Thereaction mixture is refluxed for 1 h, cooled and evaporated. The residueis partitioned between water and ethyl acetate. The organic layer isseparated, dried over sodium sulfate and evaporated to yield the titlecompound.

The starting material is prepared as follows:

A solution of 1,9 g of ethyl p-cyanophenylacetate in 50 ml of diglyme isadded to a slurry of 0.48 g of sodium hydride (50% oil dispersion) in 10ml of diglyme. The reaction mixture is stirred at room temperature for 2h, cooled to 0° and 1.75 g of N-bromosuccinimide is added portionwise.The solvent is evaporated under high vacuum and the residue ischromatographed on 50 g of silica with ether to yieldethyl-α-bromo-p-cyanophenylacetate.

A solution of 97.0 g of4-(3-trimethylsilyloxypropyl)-1H-imidazole-1-N,N-dimethyl-carboxamideand 72.0 g of ethyl-α-bromo-p-cyanophenylacetate in 500 ml ofacetonitrile is refluxed for 10 h. The solution is cooled to 0° in anice bath and ammonia gas is bubbled in for a few minutes. The mixture isthen evaporated in vacuo to give a residue which is dissolved in 500 mlof 1N hydrochloric acid. The solution is allowed to stand at roomtemperature for 15 min and then is extracted with ether. The pH of theaqueous phase is adjusted to 9 with 50% sodium hydroxide and the mixtureis then extracted with methylene chloride. The methylene chlorideextracts are washed with water, dried over sodium sulfate and evaporatedto give 1-(α-ethoxycarbonyl-p-cyanobenzyl)-1H-imidazole-5-propanol.

To a solution of 5.75 g of thionylchloride in 80 ml of methylenechloride is added 8.4 g of1-(α-ethoxycarbonyl-p-cyanobenzyl)-1H-imidazole-5-propanol as a solid inportions. When addition is complete, the solution is refluxed for 1.5 h,cooled in ice and filtered to obtain5-(3-chloropropyl)-1-(α-ethoxycarbonyl-p-cyanobenzyl)-1H-imidazolehydrochloride. The salt is partitioned between methylene chloride andsaturated sodium bicarbonate. The organic extracts were washed withwater, dried over sodium sulfate and evaporated to yield the free base.

A solution of 8.1 g of5-(3-chloropropyl)-1-(α-ethoxycarbonyl-p-cyanobenzyl)-1H-imidazole in 50ml of tetrahydrofuran is cooled to 0° in an ice bath. To this is added8.0 g of potassium-t-butoxide as a solid in portions. The mixture isstirred at room temperature for 2 h, neutralized with 10% acetic acidand partitioned between methylene chloride and water. The organic layeris washed with water, dried over magnesium sulfate and evaporated toyield an oil which is dissolved in a small volume of acetone andneutralized with ethereal hydrogen chloride. The solid is collected toyield5-(p-cyanophenyl)-5-ethoxycarbonyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine.

EXAMPLE 24 5-(p-Cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A solution of 2.13 g of5-(p-aminophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine in 4 ml ofconcentrated hydrochloric acid and 10 ml of water is added in anice-bath and a solution of 0.78 g of sodium nitrite in 2 ml of water isadded slowly. The solution is added via dropping funnel to an ice cooledsolution of 3.0 g of copper(I) cyanide in 10 ml of water, keeping thetemperature between 30°-40°. The reaction mixture is heated on a steambath for 1 hr, cooled and brought to pH 9. The organic extracts aredried over sodium sulfate and evaporated and the residue ischromatographed on silica gel with ethyl acetate to yield the titlecompound.

EXAMPLE 25 5-(p-Aminophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine

A solution of 2.42 g of5-(p-carboxyphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine in 100 mlof ethylene dichloride is treated with 6 ml of concentrated sulfuricacid. The reaction mixture is heated to 40° and 6 ml of hydrazoic acid(2M in ethylene dichloride) is added dropwise. When gas evolution hasceased, the reaction mixture is evaporated. The residue is redissolvedin water and adjusted to pH 10. The aqueous phase is extracted withmethylene chloride (3×30 ml). The organic extracts are dried overpotassium carbonate and evaporated to yield the title compound.

EXAMPLE 26

Preparation of 10,000 tablets each containing 10 mg of the activeingredient:

    ______________________________________                                        Formula:                                                                      ______________________________________                                        5-(p-Cyanophenyl)-5,6,7,8-tetrahydro-                                                               100.00 g                                                imidazo[1,5-a]pyridine                                                        Lactose               2535.00 g                                               Corn starch           125.00 g                                                Polyethylene glycol 6,000                                                                           150.00 g                                                Magnesium stearate     40.00 g                                                Purified water        q.s.                                                    ______________________________________                                    

All the powders are passed through a screen with openings of 0.6 mm.Then the drug substance, lactose, magnesium stearate and half of thestarch are mixed in a suitable mixer. The other half of the starch issuspended in 65 ml of water and the suspension is added to the boilingsolution of the polyethylene glycol in 260 ml of water. The paste formedis added to the powders, which are granulated, if necessary, with anadditional amount of water. The granulate is dried overnight at 35°,broken on a screen with 1.2 mm openings and compressed into tablets,using concave uppers bisected.

Analogously tablets are prepared containing the other compoundsdisclosed and exemplified herein.

EXAMPLE 27

Preparation of 1,000 capsules each containing 20 mg of the activeingredient:

    ______________________________________                                        Formula:                                                                      ______________________________________                                        5-(p-Cyanophenyl)-5,6,7,8-tetrahydro-                                                                20.0 g                                                 imidazo[1,5-a]pyridine                                                        Lactose                207.0 g                                                Modified starch        80.0 g                                                 Magnesium stearate      3.0 g                                                 ______________________________________                                    

All the powders are passed through a screend with openings of 0.6 mm.Then the drug substance is placed in a suitable mixer and mixed firstand the magnesium stearate, then with the lactose and starch untilhomogeneous. No. 2 hard gelatin capsules are filled with 310 mg of saidmixture each, using a capsule filling machine.

Analogously capsules are prepared, containing the other compoundsdisclosed and exemplified herein.

EXAMPLE 28

A solution of 5-(p-hydroxymethylphenyl)imidazo[1,5-a]pyridine (0.52 g)in 10 ml of methylene chloride is refluxed with 5.2 g of activatedmanganese dioxide for 24 h. An additional 5.2 g of manganese dioxide isadded and the reaction mixture is refluxed an additional 6 h, filtered,and the solvent is evaporated to yield5-(p-formylphenyl)-imidazo[1,5-a]pyridine, m.p. 144°-146°.

EXAMPLE 29

A solution of 0.18 g of 5-(p-carboxyphenyl)imidazo[1,5-a]pyridinehydrochloride in 5 ml of thionyl chloride is refluxed for 30 min andevaporated to dryness. The resulting oil is redissolved in 10 ml ofmethylene chloride and ammonia is bubbled into the solution at 0° for 1h. The solution is washed with water and dried over sodium sulfate.Evaporation yields 5-(p-carbamoylphenyl)imidazo[1,5-a]pyridine, m.p.228°-230° (dec.).

EXAMPLE 30

A solution of 3.13 g of4-[3-(4-tert-butylaminocarbonylphenyl)-3-chloroprop-1-yl]-1-titylimidazolein 150 ml of acetonitrile is refluxed for 15 h, cooled and 150 ml ofmethanol is added. The reaction mixture is refluxed an additional 15 hand evaporated to dryness. The residue is partitioned between ether andwater. The ether layer is separated and washed with 1N HCl (2×15 ml).The combined aqueous extracts are adjusted to pH=8 and extracted withmethylene chloride which is dried over sodium sulfate, filtered andevaporated to a white foam. The product is crystallized from ether toyield 1.30 g of5H-5-(4-tert-butylaminocarbonylphenyl)-6,7-dihydropyrrolo[1,2-c]imidazole,m.p. 136°-139°.

The starting material is prepared as follows:

(a) A solution of 6.0 g of methyl 3-(1H-imidazol-4-yl)propionate and 11ml of triethylamine in 31 ml of dimethylformamide is treated with asolution of 9.65 g of triphenylmethyl chloride in 110 ml ofdimethylformamide for 2 h at room temperature under nitrogen. Thereaction mixture is poured onto 700 g of ice, and the resulting solid iscollected by filtration and recrystallized from ether to yield 13.83 gof methyl 3-(1-tritylimidazol-4-yl)propionate, NMR (CDCl₃) δ=2.75 (m,4H), 3.05 (s, 3H), 6.5-7.5 (m, 17H).

(b) A solution of 44.4 mmole of diisobutylaluminium hydride in 29 ml oftoluene is added to a solution of 8.79 g of methyl3-(1-tritylimidazol-4-yl)propionate in 175 ml of methylene chloride at-72° under nitrogen. After 5 min the reaction is quenched by adding 14ml of methanol followed by 90 ml of water. The reaction mixture isallowed to warm to room temperature and is filtered through celite. Theorganic phase is separated, dried over sodium sulfate and evaporated toa yellow oil which is chromatographed on 280 g of silica with ether toyield 4.13 g of 3-(1-tritylimidazol-4-yl)propionaldehyde as an oil. IR(CDCl₃): 2830, 2740, 1730 cm⁻¹.

(c) A solution of 25 mmoles of n-butyllithium in 10 ml of hexane isadded dropwise to a solution of 3.19 g of N-tert-butyl 4-bromobenzamidein 250 ml of tetrahydrofuran at -70° under argon. After 30 min, asolution of 3.74 g of 3-(1-tritylimidazol-4-yl)propionaldehyde in 100 mlof tetrahydrofuran is added slowly. The reaction mixture is stirred at-70° for 30 min, allowed to warm to 25°, stirred at 25° for 2.5 h andquenched with excess saturated ammonium chloride solution. The aqueouslayer is separated and extracted with methylene chloride (2×100 ml). Thecombined organic extracts are dried over sodium sulfate and evaporated.The residue is chromatographed on 220 g of silica with 5:1 ether:ethylacetate to yield4-[3-(4-tert-butylaminocarbonylphenyl)-3-hydroxyprop-1-yl]-1-tritylimidazoleas an oil. IR (CH₂ Cl₂): 1660 cm⁻¹.

(d) A solution of 3.21 g of4-[3-(4-tert-butylaminocarbonylphenyl)-3-hydroxyprop-1-yl]-1-tritylimidazoleand 1.5 ml of thionyl chloride in 50 ml of methylene chloride isrefluxed for 1 h, cooled and poured into 50 ml of ice-cold sodiumbicarbonate solution. The organic phase is separated, dried over sodiumsulfate and evaporated to yield4-[3-(4-tert-butylaminocarbonylphenyl)-3-chloroprop-1-yl]-1-tritylimidazoleas a white foam. NMR (CDCl₃): δ=1.45 (s, 9H), 4.30 (t, J=6.0 Hz, 2H).

EXAMPLE 31

A solution of 1.25 g of5H-5-(4-tert-butylaminocarbonylphenyl)-6,7-dihydropyrrolo[1,2-c]imidazolein 10 ml of thionyl chloride is refluxed for 1 h, cooled and evaporated.The residue is redissolved in 10 ml of chloroform at 0° and 10 ml ofice-cold conc. ammonium hydroxide is slowly added. The aqueous layer isseparated, extracted with chloroform (3×20 ml) and the combined organicextracts are dried over sodium sulfate. Filtration, evaporation andchromatography on 45 g of silica with 5% ammonium hydroxide in ethylacetate, provides an oil which is treated with 1 molar equivalent ofethereal hydrogen chloride to yield 0.5 g of5H-5-(4-cyanophenyl)-6,7-dihydropyrrolo[1,2-c]imidazole, m.p. 227°-228°.

EXAMPLE 32

A solution of 1.29 g of5H-5-(4-tert-butylaminocarbonylphenyl)-6,7,8,9-tetrahydroimidazo[1,5-a]azepinein 10 ml of thionyl chloride is refluxed for 1 h, cooled and evaporated.The residue is partitioned between methylene chloride and ice-coldsodium bicarbonate solution. The aqueous layer is separated andextracted with methylene chloride (3×15 ml). The combined organic layersare dried over sodium sulfate and evaporated. The resulting oil ischromatographed on 26 g of silica with 5% methanol in methylenechloride. The product is treated with one molar equivalent of fumaricacid in ethanol to yield5H-5-(4-cyanophenyl)-6,7,8,9-tetrahydroimidazo[1,5-a]azepine, m.p.153°-155°.

The starting material is made from ethyl5-(1-tritylimidazol-4-yl)-1-pentonoate in an identical manner to thepreparation of5H-5-(4-tert-butylaminocarbonylphenyl)-6,7-dihydropyrrolo[1,2-c]imidazolefrom ethyl 3-(1-tritylimidazol-4-yl)propionate which is prepared asfollows:

(a) A solution of 5.6 ml of diisopropylamine in 150 ml oftetrahydrofuran at -70° under nitrogen is treated with 14.5 ml of 2.5Mn-butyllithium for 30 min and 7.2 ml of triethylphosphonoacetate isadded dropwise. After 30 min, a solution of 10.09 g of3-(1-tritylimidazol-4-yl)propionaldehyde in 50 ml of tetrahydrofuran isadded slowly. The reaction mixture is allowed to warm slowly to roomtemperature, stirred for 15 h and quenched with excess saturatedammonium chloride solution. The aqueous layer is separated and extractedwith ethyl acetate (2×50 ml). The combined organic extracts are driedover sodium sulfate and evaporated to an oil (15.35 g), which ischromatographed on 430 g of silica with ether to yield 9.61 g of ethyl5-(1-tritylimidazol-4-yl)-1-pent-2-enoate, m.p. 86°-88°.

(b) A solution of 9.20 g of ethyl5-(1-tritylimidazol-4-yl)-1-pent-2-enoate in 460 ml of anhydrous ethanolis hydrogenated with 1.88 g of 10% palladium on charcoal at atmosphericpressure for 20 min. The catalyst is removed by filtration throughcelite. Evaporation provides a solid which is recrystallised from hexaneto yield 8.64 g of ethyl 5-(1-tritylimidazol-4-yl)-1-pentanoate, m.p.84°-86°.

EXAMPLE 33

A solution of 1.27 g of ethyl5-[1-(4-cyanobenzyl)imidazol-5-yl)-1-pent-2-enoate in 27 ml oftetrahydrofuran at 5° under nitrogen is treated with 0.52 g of potassiumtert-butoxide. The reaction mixture is stirred at 5° for 2 h and 10 mlof 1N hydrochloric acid is added. The layers are separated. The organicphase is extracted with 1N hydrochloric acid (2×10 ml). The combinedaqueous layers are extracted with ether, adjusted to pH=8 and extractedwith methylene chloride (3×15 ml). The organic phase is dried andevaporated to yield the product which is treated with one molarequivalent of ethereal hydrogen chloride. The resulting solid isrecrystallized from acetone to yield5-(4-cyanophenyl)-6-ethoxycarbonylmethyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine,m.p. 126°-127°.

The starting material is prepared as follows:

(a) A solution of 2.9 ml of dry dimethylsulfoxide in 250 ml of methylenechloride is cooled to -78° under nitrogen and 2.1 ml of oxalyl chlorideis added dropwise. After 30 min at -78°, a solution of 5.0 g of3-[1-(4-cyanobenzyl)imidazol-5-yl]-1-propanol in 18 ml ofdimethylsulfoxide is added slowly. The reaction mixture is stirred for 2h and 10.4 ml of triethylamine is added. Then it is allowed to warm toroom temperature and is washed with water (4×100 ml). The organic phaseis dried over sodium sulfate and evaporated to yield 4.13 g of3-[1-(4-cyanobenzyl)imidazol-5-yl]-1-propionaldehyde. IR (CH₂ Cl₂):2750, 2250, 1732 cm⁻¹.

(b) A solution of 23 mmoles of lithium diisopropylamide, from 3.2 ml ofdiisopropylamine and 9.2 ml of 2.5M n-butyllithium, in 170 ml oftetrahydrofuran at 0° under nitrogen, is cooled to -78° and 4.2 ml oftriethylphosphonoacetate is added dropwise. After 30 min, a solution of4.1 g of 3-[1-(4-cyanobenzyl)imidazol-5-yl]-1-propionaldehyde in 30 mlof tetrahydrofuran is added slowly. The reaction mixture is stirred at-78° for 2 h, allowed to warm to room temperature and stirred anadditional 15 h before being quenched with excess saturated ammoniumchloride solution. The aqueous layer is separated and extracted withethyl acetate (2×50 ml). The combined organic layers are dried oversodium sulfate and evaporated to a yellow oil which is chromatographedon 20 g of silica gel using ether, ethyl acetate (1:1) as eluant toyield 3.56 g of ethyl 5-[1-(4-cyanobenzyl)imidazol-5-yl]-1-pent-2-enoate. IR (CH₂ Cl₂): 2240, 1720cm⁻¹.

EXAMPLE 34

A solution of 0.21 g of5-(4-cyanophenyl)-6-ethoxycarbonylmethyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinehydrochloride in 1.2 ml of ethanol and 1.2 ml of 1N sodium hydroxide isstirred at room temperature for 15 h, evaporated and the residue isredissolved in water. The aqueous phase is extracted with ethyl acetate,adjusted to pH=2, reextracted, neutralized and evaporated. The residueis triturated with tetrahydrofuran. The organic phase is treated withethereal hydrogen chloride and 0.12 g of5-(4-cyanophenyl)-6-carboxymethyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine,m.p. 209°-211°, is collected.

EXAMPLE 35

A solution of 0.80 mmoles of lithium diisopropylamide, prepared from0.12 ml of diisopropylamine and 0.32 ml of 2.5M n-butyllithium in 6 mlof tetrahydrofuran at 0°, is slowly added to a solution of 0.17 g of5-(4-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine in 2 ml oftetrahydrofuran at -78°. After 0.5 h, 0.1 ml of benzyl bromide is addeddropwise. The reaction mixture is stirred for an additional 1 h,quenched with 5 ml of water, made acidic with 1N hydrochloric acid,diluted with 20 ml of ether and the layers are separated. The aqueousphase is adjusted to pH=7, extracted with ethyl acetate (3×15 ml) andthe organic extracts are dried over sodium sulfate. Filtration andevaporation produces a foam which is treated with one molar equivalentof ethereal hydrogen chloride to yield5-benzyl-5-(4-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinehydrochloride, m.p. 249°-251°.

EXAMPLE 36

7-(p-Cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinehydrochloride, m.p. 253°-254°, is prepared by a similar sequence oftransformations from 4-(p-ethoxycarbonylphenyl)pyridine as described inexamples 4, 8-10 and 7.

EXAMPLE 37

7-(p-Carbamoylphenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine fumarate,m.p. 193°-195°, is prepared by a similar sequence of transformationsfrom 4-(p-ethoxycarbonylphenyl)pyridine as described in examples 4 and8-10.

EXAMPLE 38

A solution of 1.65 g of5-(p-cyanophenyl)-3-ethoxycarbonyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinein 10 ml of methanol containing 0.2 g of sodium hydroxide is stirred for3 h at room temperature. The solution is warmed to reflux and 5 ml of 1Nhydrochloric acid is added. After 1 h the reaction mixture is cooled andevaporated. The residue is partitioned between water and ethyl acetate.The organic layer is separated, dried over sodium sulfate and evaporatedto yield 5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine,m.p. 128°-131°.

The starting material is prepared as follows:

A solution of 2.0 g of 2-aminomethyl-6-(p-cyanophenyl)pyridine in 20 mlof methylene chloride at -15° under nitrogen is treated with 1.4 g ofethyl oxalyl chloride. The reaction mixture is allowed to warm to roomtemperature over 2 h and the solvent is evaporated. The residue isdissolved in 30 ml of phosphorus oxychloride, the reaction mixture isrefluxed for 15 h, and evaporated to dryness. The residue is partitionedbetween methylene chloride and sodium bicarbonate solution. The organicphase is separated, dried over sodium sulfate and evaporated to yield anoil which is chromatographed on 100 g of silica gel with ethyl acetateas eluant to provide5-(p-cyanophenyl)-3-ethoxycarbonyl-imidazo[1,5-a]pyridine.

A solution of 1.1 g of5-(p-cyanophenyl)-3-ethoxycarbonyl-imidazo[1,5-a]pyridine in 30 ml ofethanol is hydrogenated with 0.1 g of 10% Pd on charcoal at 1 bar for 2h, filtered and evaporated to dryness. The resulting oil is partitionedbetween water and ethyl acetate. The organic phase is separated, driedover sodium sulfate and evaporated. The residue is chromatographed on 40g of silica gel with ethyl acetate to yield5-(p-cyanophenyl)-3-ethoxycarbonyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine.

EXAMPLE 39

A solution of 0.24 g of 1-(p-cyanophenyl)-4-(4-imidazolyl)-1-butanone in20 ml of methanol at room temperature is treated with 0.2 g of sodiumcyanoborohydride. The pH is adjusted and maintained at 5.5-6.0 byaddition of concentrated hydrochloric acid. The reaction mixture isstirred for 2 h, adjusted to pH 2, and evaporated to dryness. Theresidue is taken up in methylene chloride and washed with saturatedsodium bicarbonate. The organic layer is dried over sodium sulfate andevaporated to yield5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine.

The starting material is prepared as follows:

6,95 g of N-tert-butyl-p-bromobenzamide is dissolved in 175 ml oftetrahydrofuran at -70° under nitrogen and 20.1 ml of n-butyllithium(2.7M) is added dropwise. After 30 min, a solution of 5.35 g of4-(1-trityl-4-imidazolyl)-butanoic acid in 10 ml of tetrahydrofuran isadded slowly. The reaction mixture is allowed to warm slowly to roomtemperature and 20 ml of an aqueous ammonium chloride solution is added.The organic layer is separated, dried over sodium sulfate and evaporatedto yield1-(p-N-tert-butylaminocarbonylphenyl)-4-(1-trityl-4-imidazolyl)-1-butanone

A solution of 0.5 g of1-(p-N-tert-butylaminocarbonylphenyl)-4-(1-trityl-4-imidazolyl)-1-butanonein 20 ml of thionyl chloride is refluxed for 3 h and poured into 100 mlof ice-water. The aqueous phase is extracted with ether (3×20 ml),adjusted to pH=10 and reextracted with methylene chloride. The organicphase is dried and evaporated to yield1-(p-cyanophenyl)-4-(4-imidazolyl)-1-butanone.

EXAMPLE 40

Racemic 5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridinehydrochloride is applied, in 20 mg aliquots, to a 4.6×250 mmbeta-cyclodextrin bonded silica gel column using 7:3 water:methanol asthe eluant at a flow rate of 0.8 ml/min. The separate fractions areevaporated under vacuum to yield(-)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, [α]_(D)²⁵ =-89.2° and(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine, [α]_(D)²⁵ +85.02°. Both compounds are separately dissolved in acetone andtreated with 1 molar equivalents of ethereal hydrogen chloride to yieldthe hydrochloride salts, m.p. 82°-83° (amorphous) and m.p. 218°-220°,respectively.

EXAMPLE 41

In a manner analogous to the previous examples, also the followingcompounds can be prepared:

5-(m-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine,

5-(o-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine,

5H-5-(3-cyanophenyl)-6,7-dihydropyrrolo[1,2-c]imidazole,

5H-5-(2-cyanophenyl)-6,7-dihydropyrrolo[1,2-c]imidazole,

5-(m-cyanophenyl)imidazo[1,5-a]pyridine,

5-(o-cyanophenyl)imidazo[1,5-a]pyridine,

6-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine,

8-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine.

What is claimed is:
 1. A compound of the formula ##STR30## wherein ndenotes 0, 1, 3 or 4;R₁ represents hydrogen, lower alkyl; lower alkylsubstituted by hydroxy, lower alkoxy, lower alkanoyloxy, lower alkanoyl,amino, lower alkylamino or di-lower alkylamino, halogen, sulfo,sulfamoyl, carboxy, lower alkoxycarbonyl, carbamoyl or cyano; nitro,halogen, hydroxy, lower alkoxy, aryloxy, aryl-lower alkoxy, loweralkanoyloxy, aroyloxy, lower alkoxycarbonyloxy, mercapto, loweralkylthio, arylthio, aryl-lower alkylthio, aryl-sulfinyl, aryl-sulfonyl,lower alkyl-sulfinyl, lower alkylsulfonyl, lower alkanoylthio, amino,lower alkylamino, arylamino, aryl-lower alkylamino, lower alkanoylamino,aroylamino, di-lower alkylamino; pyrrolidino, piperidino, morpholino,thiomorpholino or optionally 4-lower alkylsubstituted piperazino;quaternary ammonium derived from a disubstituted amino group mentionedabove which contains as quaternary substituent lower alkyl, hydroxy- orhalo-lower alkyl or aryl-lower alkyl; sulfo, lower alkoxysulfonyl,sulfamoyl, lower alkylsulfamoyl, di-lower alkylsulfamoyl, formyl orformyl as a di-lower alkyl acetal derivative; iminomethyl which may beN-substituted by hydroxy, lower alkoxy, lower alkanoyloxy, lower alkyl,aryl or amino; C₂ -C₂₀ -alkanoyl, halo-C₂ -C₇ -alkanoyl, aroyl, cyano,carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di-loweralkylcarbamoyl or hydroxycarbamoyl; R₂ represents hydrogen, lower alkyl;lower alkyl substituted by aryl, carboxy or lower alkoxycarbonyl;hydroxy, lower alkoxy, aryloxy, aryl-lower alkoxy, lower alkanoyloxy,aroyloxy, lower alkoxycarbonyloxy, mercapto, lower alkylthio, arylthio,aryl-lower alkylthio, aryl-sulfinyl, aryl-sulfonyl, lower alkylsulfinyl,lower alkylsulfonyl, lower alkanoylthio, C₂ -C₂₀ -alkanoyl, halo-C₂ -C₇-alkanoyl, aroyl, cyano, carboxy, lower alkoxycarbonyl, carbamoyl, loweralkyl-carbamoyl, di-lower alkylcarbamoyl or hydroxycarbamoyl; aroylwithin said definitions represents arylcarbonyl; and aryl within any ofthe above definitions represents 1- or 2-naphthyl, phenyl, or phenylsubstituted by lower alkyl, lower alkoxy or halogen;or apharmaceutically acceptable salt thereof.
 2. A compound according toclaim 1 of formula I* whereinn denotes 1 or 3; R₁ represents loweralkyl; lower alkyl substituted by hydroxy, amino, di-lower alkylamino,by 1 to 5 fluorine atoms, by carboxy, lower alkoxycarbonyl, carbamoyl orcyano; nitro, halogen, hydroxy, lower alkoxy, amino, lower alkylamino,di-lower alkylamino, sulfo, sulfamoyl, formyl, iminomethyl; iminomethylN-substituted by hydroxy, lower alkoxy, lower alkanoyloxy, lower alkylor phenyl; carboxy, lower alkoxycarbonyl, carbamoyl, loweralkylcarbamoyl, di-lower alkylcarbamoyl or cyano; R₂ representshydrogen, lower alkyl, phenyl-lower alkyl, carboxy-lower alkyl, loweralkoxycarbonyl-lower alkyl, halogen, lower alkoxy, lower alkylthio,phenyl-lower alkylthio, phenylthio, carboxy, lower alkoxycarbonyl orlower alkanoyl; or a pharmaceutically acceptable salt thereof.
 3. Acompound according to claim 1 of the formula ##STR31## wherein n denotes1 or 3;R₁ represents lower alkyl, amino, lower alkylamino, di-loweralkylamino, hydroxymethyl, halogen, formyl, carboxy, loweralkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoylor cyano; and R₂ is hydrogen, lower alkyl, phenyl-lower alkyl,carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower alkylthio,carboxy or lower alkoxycarbonyl;or a pharmaceutically acceptable saltthereof.
 4. A compound according to claim 1 of formula I*, whereinndenotes 1 or 3; R₁ represents lower alkyl, hydroxy-lower alkyl, halogen,amino, formyl, carboxy, lower alkoxycarbonyl, carbamoyl, N-loweralkylcarbamoyl or cyano; R₂ represents hydrogen, lower alkylthio, loweralkoxycarbonyl, phenyl-lower alkyl, carboxy-lower alkyl or loweralkoxycarbonyl-lower alkyl;or a pharmaceutically acceptable saltthereof.
 5. A compound according to claim 3 whereinn represents 1 or 3;R₁ represents cyano or halogen; and R₂ is hydrogen, lower alkyl,phenyl-lower alkyl, carboxy-lower alkyl, lower alkoxycarbonyl-loweralkyl, lower alkylthio, carboxy or lower alkoxycarbonyl; the twosubstituents C₆ H₄ --R₁ and R₂ to be attached to any of the saturatedcarbon atoms of the saturated ring, either both to the same carbon atomor to different carbon atoms;or a pharmaceutically acceptable saltthereof.
 6. A compound according to claim 3 whereinn represents 1 or 3;R₁ represents cyano or halogen; R₂ represents hydrogen;or apharmaceutically acceptable salt thereof.
 7. A compound according toclaim 6 whereinn represents 1;or a pharmaceutically acceptable saltthereof.
 8. A compound according to claim 6 whereinn represents 3;or apharmaceutically acceptable salt thereof.
 9. A compound according toclaim 6 wherein the substituent C₆ H₄ --R₁ is attached to the 5-positionof the bicyclic ring system; or a pharmaceutically acceptable saltthereof.
 10. A compound according to claim 9 whereinR₁ representscyano;or a pharmaceutically acceptable salt thereof.
 11. A compoundaccording to claim 2 of the formula I* whereinn represents 1;or apharmaceutically acceptable salt thereof.
 12. A compound according toclaim 2 of the formula I* whereinn represents 3;or a pharmaceuticallyacceptable salt thereof.
 13. A compound according to claim 4 of formulaI* whereinn represents 1;or a pharmaceutically acceptable salt thereof.14. A compound according to claim 4 of formula I* whereinn represents3;or a pharmaceutically acceptable salt thereof.
 15. A compoundaccording to claim 3 of formula I* whereinn represents 1;or apharmaceutically acceptable salt thereof.
 16. A compound according toclaim 3 of formula I* whereinn represents 3;or a pharmaceuticallyacceptable salt thereof.
 17. A compound according to claim 1 of theformula I* whereinn denotes 1;or a pharmaceutically acceptable saltthereof.
 18. A compound according to claim 1 of the formula I* whereinndenotes 3;or a pharmaceutically acceptable salt thereof.
 19. A compoundaccording to claim 18 being5H-5-(4-cyanophenyl)-6,7-dihydropyrrolo[1,2-c]imidazole or apharmaceutically acceptable salt thereof.
 20. A compound according toclaim 18 being5H-5-(4-cyanophenyl)-6,7,8,9-tetrahydroimidazo[1,5-a]azepine or apharmaceutically acceptable salt thereof.
 21. An aromatase inhibitingpharmaceutical composition comprising a compound according to claim 1 ora pharmaceutically acceptable salt thereof in combination with one ormore pharmaceutically acceptable carriers.
 22. A method of inhibitingaromatase activity in mammals which comprises administering to a mammalin need thereof an effective aromatase inhibiting amount of a compoundof according to claim 1 or of a pharmaceutical composition comprising asaid compound together with one or more pharmaceutically acceptablecarriers.
 23. A method of inhibiting thromboxane synthetase in mammalscomprising the administration to a said mammal in need thereof of aneffective thromboxane synthetase inhibiting amount of a compoundaccording to claim 1 or of a pharmaceutical composition comprising asaid compound together with one or more pharmaceutically acceptablecarriers.